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Sung Pil Ha 
 
CD4+ T cell mediated tumor immunity following transplantation of TRP-1 TCR 
gene modified hematopoietic stem cells 
 
Immunotherapy for cancer has held much promise as a potent modality of 
cancer treatment.  The ability to selectively destroy diseased cells and leave 
healthy cells unharmed has been the goal of cancer immunotherapy for the past 
thirty years.  However, the full capabilities of cancer immunotherapies have been 
elusive.  Cancer immunotherapies have been consistently hampered by limited 
immune reactivity, a diminishing immune response over time, and a failure to 
overcome self-tolerance.   Many of these deficiencies have been borne-out by 
immunotherapies that have focused on the adoptive transfer of activated or 
genetically modified mature CD8+ T cells.  The limitations inherent in therapies 
involving terminally differentiated mature lymphocytes include limited duration, 
lack of involvement of other components of the immune system, and limited 
clinical efficacy.  We sought to overcome these limitations by altering and 
enhancing long-term host immunity by genetically modifying then transplanting 
HSCs.  To study these questions and test the efficiency of gene transfer, we 
cloned a tumor reactive HLA-DR4-restricted CD4+ TCR specific for the 
melanocyte differentiation antigen TRP-1, then constructed both a high 
expression lentiviral delivery system and a TCR Tg expressing the same TCR 
vi 
 
genes.  We demonstrate with both mouse and human HSCs durable, high-
efficiency TCR gene transfer, following long-term transplantation.  We 
demonstrate the induction of spontaneous autoimmune vitiligo and a TCR-
specific TH1 polarized memory effector CD4+ T cell population.  Most importantly, 
we demonstrate the destruction of subcutaneous melanoma without the aid of 
vaccination, immune modulation, or cytokine administration.   Overall, these 
results demonstrate the creation of a novel translational model of durable 
lentiviral gene transfer, the induction of spontaneous CD4+ T cell immunity, the 
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T Cell Development Overview 
 T lymphocytes, like all cellular components of blood are ultimately derived 
from and dependent on constant regeneration from hematopoietic stem cells 
(HSCs) found in bone marrow.  HSCs are characterized by their multi-lineage 
potential and self-renewal capacity.  HSCs continuously give rise to lineage-
restricted progenitor cells including myeloid progenitors, erythroid progenitors, 
and common lymphoid progenitor cells.  Lymphoid progenitors continue their 
maturation in secondary lymphoid tissue.  Primarily, B cells mature in the bone 
marrow and T cells mature in the thymus, thus their respective names.  Since the 
crux of this thesis, involves the selection and manipulation of the T cell 
population, we will focus on T cell development.   
Hematopoietic Stem Cells 
 HSCs are fully capable of self-renewal and differentiation into all the 
cellular components of blood.  Because of their pluripotent nature, HSCs hold 
great therapeutic promise.  In particular, manipulation of the genes involved in 
HSC development would mean the alteration of all cellular progeny downstream 
of these early precursor cells.  Thus, much research has gone into identifying 
and characterizing these HSCs and their early decedent progenitor cell 
populations.  HSCs are identified in mice by a distinct surface protein phenotype, 
Lin-/Sca-1+/c-kit+/CD44+/CD25-.  They further differentiate in the bone marrow to 
become lymphoid biased progenitor cells including LSK CD62L cells (Lin-/Sca-
1+/c-kit+/CD62L+), early lymphoid precursors (ELP) (Lin-/Sca-1+/c-
kit+/Flt3+/CD27+), and common lymphoid precursors (CLP) (Lin-/Sca-1-/c-kit-/IL-
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7Ra+).  A common theme amongst these early progenitor cells is the absence of 
lineage markers and the expression of c-kit and Sca-1, along with the capacity to 
traffic to and efficiently proliferate in the thymus, and their propensity to 
differentiate into lymphoid cells (Haddad et al, 2004; Wu, 2006; Hoebeke et al, 
2007; Serwold et al, 2008; Awong et al, 2009).   
Thymic Development 
 Lymphoid progenitor cells subsequently traffic to the thymus, a secondary 
lymphoid organ devoted to the development, selection, and maturation of T cells.  
T cell progenitors originating from bone marrow are released in waves into the 
blood where they travel periodically to the thymus (Miller, 1961; Pullen et al, 
1989).  These immature thymocytes undergo two phases of selection, both 
positive and negative.  In positive selection, thymocytes recognizing binding 
components of MHC molecules are promoted and activated while thymocytes 
that do not recognize self MHC molecules are actively deleted (Bevan and Fink, 
1978; Zinkernagel et al, 1978; Pullen et al, 1989).  In negative selection, 
thymocytes that recognize self-antigens are actively deleted thus ensuring 
removal of mature lymphocytes capable of inducing autoimmunity (von Boehmer 
et al, 1989; McDonald and Lees, 1990).  This process of central tolerance is 
critical for the prevention of autoimmunity (Schwartz, 1989).  Thymic epithelial 
cells are believed to play a significant role in the negative selection process.  In 
particular, the medullary thymic epithelial cells (mTECs) which express the 
autoimmune regulator element (AIRE), a regulatory transcription factor which 
controls the promiscuous expression of a variety of self-antigens in mTECs 
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allows for the negative selection of self-antigen binding thymocytes.  The genes 
activated by AIRE include genes for a broad spectrum of protein functional 
classes (growth factors, hormones, structural molecules, and tissue specific 
proteins that represent essentially every organ) (Gotter et al, 2004; Johnnidis et 
al, 2005; Anderson et al, 2005).   
Immunotherapy 
 As evidenced above, researchers have taken great strides in uncovering 
the nature, development and selection of the cells of the immune system.  
However, this knowledge has not necessarily translated into clinical therapies.  
The early attempts to harness the vast therapeutic potential of the immune 
system focused primary on global manipulation of the immune response via 
application of supraphysiologic levels of cytokines.  Initial immunotherapies for 
cancer focused on the activation of immune cells by administration of high dose 
interleukin-2 (IL-2).  Early studies in the 1980s identified cells capable of directly 
lysing fresh tumors by incubation of lymphocytes in IL-2 (Yron et al, 1980).   
Subsequent adoptive transfer of these lymphokine activated killer (LAK) cells in 
conjunction with IL-2 therapy mediated the regression of some advanced 
metastatic cancers.  Of 55 patients treated with this approach, 21 showed 
objective clinical regression, and 5 individuals showed complete regression of 
malignancy (Rosenberg, 1985).  These early trials showed promise in stimulating 
immune response to metastatic melanoma; however, the high doses of IL-2 
required for clinical response were intolerable to the majority of patients and 
mediated toxic side effects, the most common of which was a capillary 
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permeability leak syndrome that resulted in major fluid retention. Furthermore, 
the large number of activated cells necessary to mediate tumor regression was 
cumbersome and limited the practicality of treatment on a large scale 
(Rosenberg et al, 1985; Rosenberg et al, 1986). Treatment approaches with 
cancer vaccines and more advanced adoptive immunotherapies have had 
similarly limited outcomes.  Due to these limitations, in the past three decades 
researchers have sought more efficient approaches to modify the immune 
response to cancer.    
Discovery of Tumor Infiltrating Lymphocytes 
 In 1986, Rosenberg, Spiess, and LaFreniere at the National Cancer 
Institute of the NIH discovered a subpopulation of lymphocytes that infiltrate into 
growing cancers and were 50 to 100 times more potent than LAK cells for use in 
adoptive transfer therapies (Rosenberg et al, 1986).  These tumor infiltrating 
lymphocytes (TIL) could be expanded ex vivo by incubation with IL-2 to sufficient 
numbers for effective adoptive transfer. Concomitant TIL adoptive transfer, low 
dose IL-2 treatment and immunosuppression with cyclophosphamide proved to 
be highly effective in treating hepatic and pulmonary metastases in mice with 
colon adenocarcinoma (Rosenberg et al, 1986).   Unfortunately, early human 
trials of TIL adoptive cell transfer therapy showed only a limited ability to 
objectively regress tumor in metastatic cancer patients.  However, the isolation of 
these tumor infiltrating lymphocytes and subsequent clonal expansion of the 
lymphocytes led to the discovery of T cells specific for many melanocyte 
differentiation antigens (MDA).  CD8+ and CD4+ T cells specific for MDAs have 
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been identified, and the gene encoding the specific TCR has been sequenced.  
(Boon and van der Brugges, 1996; Kawakami and Rosenberg, 1997; Jager et al, 
1998; Renkvist et al, 2001).   
Autoimmunity Versus Tolerance 
 If tumor antigen specific lymphocytes exist both within the peripheral 
circulation and at the tumor site, then the question arises, why is there not a 
consistently observed and fully therapeutic immune response?  Although, the 
exact mechanisms are not clear, the answer lies in the balance between self-
tolerance and autoimmunity.  Immune tolerance mechanisms have evolved to 
protect the host from autoimmunity.  During the normal development of the T cell 
repertoire, self-reactive T cells are negatively selected and removed from the 
total population of T cells within the medulla of the thymus.  Medullary thymic 
epithelial cells (mTECs), under the control of the autoimmune regulator (AIRE) 
transcription factor, appear to express a range of self-antigens which allows for 
the deletion of those T cells that recognize self-antigens, a process known as 
negative selection (Gallegos and Bevan, 2004; Gotter et al, 2004; Anderson et al, 
2005; Johnnidis et al, 2005).  Thus, T cells potentially capable of reacting against 
self-antigens undergo apoptosis in the thymus and never enter the peripheral 
circulation (Anderson et al 2005).  The deletion of these self-reactive T cells is 
mediated by both direct and indirect antigen presentation by mTECs and bone 
marrow derived antigen presenting cells (APCs) (Gallegos and Bevan, 2004).  
mTECs promiscuously express a wide range of self antigens under the control of 
AIRE (Magalhaes et al, 2006).  Although, direct presentation of self-peptides by 
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mTECs can efficiently remove a subset of T cells, bone marrow derived APCs 
extend the range of clonal deletion by cross-presenting antigen captured from 
mTECs and removing those T cells.  (Gallegos and Bevan, 2005).  However, this 
thymus dependent central tolerization is clearly not absolute as witnessed by 
self-antigen specific T cells identified in autoimmune disorders and within tumors 
as TILs and circulating in the peripheral blood of cancer patients (Gallegos and 
Bevan, 2006).  
Central tolerance alone is insufficient to fully prevent autoimmunity.  Aside 
from the normal mechanisms for peripheral anergy, evidence has mounted for 
the importance of a subset of CD4+ T cells which function as regulatory T (Treg) 
cells in the periphery (Javia and Rosenberg, 2002; Baecher-Allen and Anderson, 
2006).  T cells that were able to actively suppress immune responses were 
described as early as the 1970s (Gershon and Kondo, 1971).  In the mid-1990s, 
these Treg cells, which constitute approximately 10% of CD4+ T cells, were found 
to co-express the IL-2 receptor α chain (CD25)  (Shevach 2002).  Subsequent 
isolation and in vitro  experiments have shown that Tregs phenotypically express 
cytotoxic T-lymphoctye antigen 4 (CTLA-4), CD103, and glucocorticoid induced 
TNF receptor (GITR) family related gene at high levels.  The transcription factor 
Foxp3 appears to act as the master control gene for the development and 
function of Tregs (Shevach 2002; Fontenot et al, 2003; Nishimura, et al 2004).  
Unlike, typical CD4+ T cells, Tregs do not appear to undergo activation and 
proliferation when their TCR recognizes antigen bound to MHC molecules.  
Instead, these Treg cells are both hyporesponsive and suppressive of normal 
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CD4+ and CD8+ T cell responses to specific antigens.  The exact mechanisms for 
suppression remains poorly understood.  Direct T cell to T cell interaction 
appears to be a necessary requirement for active suppression by Tregs.  
However, the function of dendritic cells and other APCs cannot be completely 
dismissed (Shevach 2002).   
 In the context of cancer immunity, tolerance to endogenously expressed 
tumor antigens limits the immune response to tumor and allows for unfettered 
tumor growth.  Tregs isolated from the peripheral blood of metastatic melanoma 
patients clearly demonstrate a hypoproliferative response to MDA presentation 
and suppressive capabilities (Javia and Rosenberg, 2003).   In one study, Treg 
cells isolated from MDA peptide vaccinated metastatic melanoma patients were 
co-cultured with CD4+CD25- T cells.  Treg cells from 11 of 13 patients 
suppressed proliferation of the CD4+CD25- T cells by an average of 60% when 
stimulated with a combination of anti-CD3 and irradiated allogeneic PBMC 
stimulus.  The suppression was directly proportional to the number of Treg cells 
in the co-culture and could be overcome with the administration of high doses of 
IL-2 (Javia and Rosenberg, 2003).     
 When the mechanisms of self tolerance are broken, autoimmune 
responses occur.  Autoimmune vitiligo has been observed as a consequence of 
immunotherapy for melanoma.  This selective autoimmune destruction of 
melanocytes is often observed with objective clinical regression of melanoma.  
Vitiligo induction has been observed in mice following vaccination with several 
MDAs including gp100, TRP-1 and TRP-2 (Hawkins et al, 2000; Overwijk et al, 
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1999; Okamoto et al, 1998).  Furthermore, adoptive transfer of gp100 and 
tyrosinase specific CD8+ T cells has also been observed to cause autoimmune 
vitiligo in mice (Overwijk et al, 2003).    Autoimmune vitiligo appears to be 
mediated by cytotoxic CD8+ T cells that recognize MDAs which home to the skin 
and lead to the destruction of pigmented cells as observed in patients with Vogt-
Koyanagi-Harada disease (Ogg et al, 1998; Sugita et al, 1996).  However, 
experiments with vaccination of knockout mice revealed a dependence on MHC 
Class II molecules as would be expected with a CD4+ T cell mediated response, 
but not MHC Class I in the induction of vitiligo.  Taken together these results 
indicate a central role for CD4+ T cells in the induction of vitiligo (Overwijk et al, 
1999).   
Myelodepletion Enhances Autoimmunity 
The balance between tolerance and autoimmunity can be skewed to favor 
autoimmunity with lymphodepletion (North,1982; Javia and Rosenberg, 2002; 
Ghiringhelli et al, 2004).  Experiments in mouse models showed that adoptive 
transfer of tumor specific lymphocytes (North, 1982) and antigen specific 
vaccination both evoked a Treg mediated immunosupression (Javia and 
Rosenberg, 2002).  Permanent regression of tumors could be achieved by 
lymphodepletion via administration of cyclophosphamide prior to adoptive 
transfer of lymphocytes (North 1982).  Accordingly, clinical trials with adoptive 
transfer of TILs demonstrated that modulation of the recipient environment by 
myelodepletion enhanced clinical responses.  In one clinical trial at the NIH, 18 of 
35 treated patients with refractory metastatic melanoma showed objective clinical 
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responses to the combination of lymphodepletion via chemotherapy, adoptive 
transfer and high dose IL-2 administration, a significantly improved result from 
prior adoptive transfer trials without lymphodepletion (Dudley et al, 2005).  Two 
mechanisms have been proposed to explain the improved results seen with 
myelodepletion: 1) the removal of Tregs which otherwise suppress transferred 
tumor reactive lymphocytes, 2) the decreased competition by endogenous 
lymphocytes for homeostatic regulatory cytokines such as IL-7 and IL-15 (Dudley 
et al, 2005).     
Limitations of CD8+ T Cells in Cancer Immunotherapy 
 Given that most tumor cells are MHC Class II negative, the bulk of current 
research on immunotherapies for cancer has revolved around CD8+ T 
lymphocytes.  Effector CD8+ T cells recognize tumor antigen presented by MHC 
Class I molecules and directly lyse the offending neoplastic cells.  CD8+ T cells 
induce cell destruction through the release of inflammatory cytokines such as 
tumor necrosis factor-α and IFN-γ, the induction of apoptosis, and cytotoxic 
degranulation leading to perforin-mediated lysis.  However, the existence of 
tumor antigen specific CD8+ T cells in metastatic cancer patients indicate that 
CD8+ T cells alone are insufficient to lead to rejection or regression of cancer 
(Dudley and Rosenberg, 2003).  Researchers have been successful in identifying 
a multitude of melanocyte differentiation antigen (MDA) specific MHC class I 
restricted CD8+ T cells including CD8+ T cells specific for gp100, TRP-1, TRP-2 
and the immunodominant MART-1 (Pardoll 1994; Boon and van der Brugges, 
1996; Kawakami and Rosenberg, 1997; Renkvist et al, 2001).  Vaccinations with 
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these peptide antigens succeeded in routinely generating tumor reactive CD8+ T 
lymphocytes in patients, but only lead to sporadic regression of tumor (Dudley 
and Rosenberg, 2003).      
Adoptive transfer of autologous T cells derived from patients with 
metastatic melanoma has proven to be effective in objective tumor regression in 
a limited number of patients.  Subsequent experiments on human patients with 
refractory metastatic melanoma have shown some clinical response to adoptive 
transfer of TILs.  Tumor reactive T cell subpopulations were selected from TILs 
by screening for cytokine secretion.  TILs were presented with lysates of 
autologous and established tumor cell lines.  T cell subpopulations with high 
recognition of tumor antigens as measured by cytokine secretion were isolated.     
TIL cultures that exhibited specific tumor recognition were expanded for 
treatment using a rapid expansion protocol with irradiated allogeneic feeder cells, 
anti-CD3 antibody, and IL-2. (Dudley et al, 2002; Dudley and Rosenberg, 2003)   
In one clinical trial, adoptive transfer of TILs in combination with administration of 
high dose IL-2, resulted in the objective regression of tumor in 51% of patients 
(18 of 35 patients) (Dudley et al, 2005).     
One limitation of adoptive transfer of TILs is the need to find preexisting 
tumor reactive colonies.  Researchers have addressed this concern by transfer of 
genetically modified CD8+ T lymphocytes.  CD8+ T cells were conferred tumor 
recognition by transduction with a retrovirus encoding a T cell receptor specific 
for a MART-1 epitope.  Adoptive transfer of these gene modified CD8+ T cells in 
15 patients resulted in tumor regression in 2 patients who maintained high levels 
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of circulating gene modified CD8+ T cells for at least one year post infusion 
(Morgan et al, 2006).   
A second limitation of adoptive cell transfer therapies is the lack of a 
permanent change in the T cell repertoire.  Persistence of antigen specific T cells 
following adoptive transfer is necessary for effective clinical regression of tumor 
(Zhou et al, 2004; Robbins et al, 2004; Zhou et al, 2005).  Telomere length has 
been positively correlated with persistence of reactive T cells following adoptive 
transfer (Zhou et al, 2005; Shen et al, 2007).  TILs proliferate extensively 
following adoptive transfer, but fail to induce substantial telomerase activity, and 
undergo rapid decreases in telomere length and quickly become replicatively 
senescent.  Those clonotypes with the shortest telomeres at the time of transfer 
become driven to senescence, while only those with longer telomeres are able to 
persist and mediate antitumor effects (Shen et al, 2007).         
 Although the adoptive transfer of CD8+ T cells shows promise, clinical 
responses have been modest.  We believe that the limited success of CD8+ T 
cells is due in part to the lack of a CD4+ T cell component to the immune 
response.  Successful immunotherapies for cancer will almost certainly require a 
CD4+ T cell response.   
Importance of CD4+ T Cells in Cancer Immunotherapy   
 CD4+ T lymphocytes play a central role in conducting the initiation and 
maintenance of the adaptive immune response (Figure 1).  It has been 
demonstrated that CD4+ T lymphocytes help the activation and expansion of 
CD8+ T cells.  In particular the release of cytokines such as IL-2, IL-12, and IFN-γ 
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by Th1 helper cells aid in the activation and expansion of CD8+ cytotoxic 
lymphocytes.  Furthermore, CD4+ T cells appear to be necessary at the time of 
priming of CD8+ T cells for the effective establishment of CD8+ T cell memory 
cells and for long term maintenance of antigen-activated CD8+ T cells (Gerloni 
and Zanetti, 2005; Williams et al, 2006).   
 Studies on the role of the CD4+ T cells in antitumor immunity have shown 
the importance of cytokines such as IL-2, IL-12, and IFN-γ to promote activation 
and expansion of CD8+ cytotoxic T lymphocytes (Gerloni and Zanetti, 2005; 
Kennedy and Celis, 2008).  Further evidence indicates that effective presentation 
of tumor antigens to CD8+ T cells may require the activation of antigen 
presenting cells (APC) by CD4+ T cells.  Tumor antigen recognition by CD4+ T 
cells and subsequent interactions between CD40 on CD4+ T cells and the CD40 
ligand on APCs activates the APC to present antigen and costimulates the 
priming of CD8+ T cells.  In this model, the activation of CD8+ T cells is achieved 
through the cross-priming of APCs by CD4+ T cells (Pardoll and Topalian, 1998; 
Bennettet al, 1998; Toes et al, 1998; Schoenberger et al, 1998).     
 Cell based vaccine models of antitumor immunity indicates that CD4+ T 
cells can mediate a CD8+ T cell independent pathway for tumor resistance.  In 
particular, there is evidence that CD4+ T cells can activate and recruit 
macrophages and eosinophils to tumor sites.  Activation of macrophages and 
eosinophils can produce reactive oxygen intermediates that can directly destroy 
tumor cells (Hock et al, 1991; Hung et al, 1998; Cohen et al, 2000). Vaccination 
of mice with a recombinant vaccinia virus encoding the murine TRP-1 antigen led 
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to autoimmune vitiligo and subsequent rejection of B16 tumor challenge.  
Vaccination of CD4+ T cell depleted mice did not develop vitiligo and failed to 
reject the tumor challenge.  In contrast, β2m knockout mice which have severely 
limited numbers of CD8+ T lymphocytes developed autoimmune vitiligo and 
resistance of B16 tumor challenge at a statistically similar rate as normal C57BL6 
mice (Overwijk et al, 1999).  In a separate study, vaccination and tumor 
challenge in nitric oxide synthase knockout mice showed a failure to reject a 
tumor challenge (Pardoll and Topalian, 1998).  Taken together these 
experiments indicate a CD8+ T cell independent pathway for activated CD4+ T 
cells in tumor resistance, perhaps through the recruitment and activation of 
macrophages and eosinophils.   
Given the pivotal position that CD4+ T lymphocytes occupy in the adaptive 
immune response, it is clear that activation of tumor antigen specific CD4+ T cells 
is necessary for effective long term immune responses to tumor.   
Isolation of TRP-1 Specific CD4+ TCR 
Researchers in our lab had previously identified an MHC Class II HLA-
DR4 restricted CD4+ T cell population capable of reacting against the naturally 
occurring TRP-1 protein (Touloukian et al, 2002).  Human lymphocytes specific 
and reactive to a 21-residue epitope of TRP-1 (positions 277-297) were isolated 
from the peripheral blood of a metastatic melanoma patient by limiting dilution.  In 
brief, peripheral blood mononuclear cells (PBMC) were collected by pheresis and 
cultured in 96 well plates at a concentration of 0.3 cells/well.   The cultures were 
subsequently stimulated with allogeneic PBMC (5x104 cells/well), IL-2 (50 
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CU/ml), and murine monoclonal anti-CD3 antibody (OKT-3) (30 ng/ml).  The cells 
were then screened for TRP-1 antigen reactivity by ELISA for cytokine release 
upon presentation with irradiated APCs loaded with TRP-1 peptide.  Positive 
clones were then expanded by further stimulation with allogeneic PBMC, IL-2, 
and OKT-3.  The selected clones were further screened for cytokine release by 
ELISA to TRP-1 peptide loaded EBV transformed B cells, tumor lysate, and 
whole tumor.  By this strategy a single clonal population of CD4+ T cells reactive 
to TRP-1 was identified.  The isolated clonal population of CD4+ T cells showed a 
dosage dependent release of IFN-γ to increasing concentration of peptide.  
Furthermore, the CD4+ T cells showed a specific response only to TRP-1 epitope 
presented in the context of the MHC Class II HLA-DR4 molecule.  
Efficiency and Safety of Lentiviral Gene Delivery 
Over the past decade γ-retroviruses (γ-RVs) have been used widely in 
both animal models and human clinical trials to introduce gene products into 
peripheral T cells, dendritic cells (DCs), and HSCs (Schnell et al, 2000; 
Cavazanna-Calvo et al, 2000; Yang et al, 2002; Moeller et al, 2005; Morris et al, 
2005; Morgan et al, 2006).  Despite their widespread use, γ-RVs appear to have 
limited intrinsic value because of several factors, including requirement of a long-
term in vitro preactivation period, limited transgene expression in early progenitor 
cells, attenuation of gene expression after progenitor differentiation and/or long-
term culture and engraftment, and ongoing fears regarding biosafety (Miller et al, 
1990; Roe et al, 1993; Gothot et al, 1998; Glimm et al, 2000; Klug et al, 2000; 
Baum, 2007).  To achieve higher levels of gene transfer, greater infectivity in 
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metabolically inactive target cells, and improved biosafety profile, recent methods 
have shifted to lentiviral (LV) technology (Woods et al, 2002; Bartosch and 
Cosset, 2004).  Unlike native HIV or HTLV, current generation lentiviral vectors 
lack the accessory components necessary for viral self-replication and have been 
modified to contain a chimeric Rous sarcoma virus/HIV 5’ LTR enhancer and a 
heterologous internal promoter (e.g. CMV, EF1α, PGK) (Woods et al, 2002).  The 
use of a stronger promoter has been shown to eliminate the need for the HIV Tat 
protein (Sastry et al, 1996).  Lentivectors have also been made self-inactivating 
(SIN) by deleting the majority of the U3 region in the 3’ LTR thereby inhibiting 
viral RNA production in target cells (Zufferey et al, 1998; Dull et al, 1998).  
Current lentiviral vectors have also been successfully used to deliver complex 
gene products into non-dividing (mitotically quiescent, G0/G1 phase) HSCs.  Most 
importantly, there is increasing evidence of enhanced persistence and biosafety 
of both genomically integrated and non-integrated vector DNA, inducing 
theoretically lower rates of insertional mutagenesis (Montini et al, 2006; Yanez-
Munoz et al, 2006).  For these reasons, we chose a lentiviral construct as our 
gene delivery vector.   
Summary 
As outlined above, T cell selection is a two step mechanism involving both 
positive and negative selection.  Lymphocytic precursor cells migrate from the 
bone marrow to the thymus.  T cells mature in the thymus which provides 
structural support for the sequence of steps necessary for T cell selection (Miller, 
1961).  Immature T cells are located in the cortex of the thymus and progress 
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through a series of alterations which can be traced by the differing expression of 
surface antigens (CD3, 4, 8, and the TCR) using surface marker specific 
antibodies.  The vast majority of thymocytes undergo apoptosis unless 
successfully selected by positive selection (McDonald and Lees, 1990).   
Positive selection is mediated by thymic cortical epithelial cells that select 
only those T cells with TCRs that recognize self-MHC molecules (Bevan and 
Fink, 1978; Zinkernagel et al, 1978; Pullen et al, 1989).  Furthermore, positive 
selection promotes the survival of only those T cells with proper matching of 
MHC molecules and co-receptor.  Thus, T cells with TCRs that recognize MHC 
class I molecules and express the CD8 co-receptor go on to mature into cytotoxic 
T cells, while those binding MHC class II molecules express CD4 and mature into 
cytokine releasing T cells (Bevan and Fink, 1978; Zinkernagel et al, 1978; 
McDonald and Lees, 1990; McDonald and Lees, 1990).  The overall effect of 
positive selection is the survival of only those T cells with TCRs that bind self-
MHC molecules and express the corresponding co-receptors.  The surviving 
maturing T cells then progress deeper into the thymic medulla where negative 
selection occurs.   
Negative selection is mediated for the large part by medullary thymic 
epithelial cells expressing AIRE and bone marrow derived dendritic cells located 
in the corticomedullary junction of the thymus and macrophages scattered 
throughout the medulla (Gallegos and Bevan, 2004; Gotter et al, 2004; Anderson 
et al, 2005; Johnnidis et al, 2005).  T cells that have been positively selected are 
presented with a wide array of self-peptides bound to MHC molecules by these 
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antigen presenting cells.   Those T cells that recognize self-antigen are lead to 
undergo apoptosis, thus removing any T cells that recognize self-antigens 
(McDonald and Lees, 1990; von Boehmer et al, 1989; Schwartz, 1989; Anderson 
et al, 2005).  The remaining T cells are released from the thymus into the 
periphery and remain small inactive mature T cells until activated by binding to 
non-self-antigens bound to MHC molecules.  The overall effect of positive and 
negative selection is two-fold.  Positive selection results in the peripheral 
circulation of only those T cells that recognizes self-MHC molecules with 
expression of the appropriate co-receptor leading to MHC restriction (Bevan and 
Fink, 1978; Zinkernagel et al, 1978; von Boehmer et al, 1989; Nikolic-Zulgic and 
Bevan; 1990).  Negative selection results in the removal of T cells that recognize 
self-antigen bound to self-MHC molecules leading to self-tolerance.  (von 
Boehmer et al, 1989; Schwartz, 1989; McDonald and Lees, 1990; Gotter et al, 
2004; Johnnidis et al, 2005; Anderson et al, 2005) 
The central tolerance mechanisms of positive and negative selection are 
not absolute as evidenced by the existence of T cells specific for self antigens in 
melanoma patients (Knuth et al, 1992; Anichini et al, 1993; Houghton, 1994; 
Topalian et al, 1994; Cox et al, 1994; Bowne et al, 1999; Bouneaud et al, 2000).  
Experiments with high doses of IL-2 have shown the existence of lymphocytes 
capable of recognizing tumor cells.  These tumor-infiltrating lymphocytes have 
been successfully cultivated in the presence of high concentrations of IL-2.  TILs 
are an oligoclonal expansion of T cells with specificity for tumor antigens that 
surround and invade the tumor.  In melanomas a series of melanocyte 
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differentiation antigens (MDA) have been identified that are specifically targeted 
by T cells.  These MDAs which in large part are associated with the membrane of 
melanosomes are glycoproteins.  Many potential melanosome antigens exist, yet 
only a few seem to be recognized by the immune system.  Furthermore, 
evidence indicates that MDAs such as MART-1, OA1 and TRP-1 are capable of 
reversing tolerance to self-antigens and inducing the proliferation of specific T 
cells reactive to self-antigens leading to autoimmune vitiligo (Okamoto et al, 
1998; Overwijk et al, 1999; Hawkins et al, 2000; Garbelli et al, 2005).     
T cells capable of recognizing melanoma antigens have clearly been 
demonstrated by the presence of MDA recognizing T cells.  TIL isolated from 
melanoma patients have yielded T cells with specificity for several MDAs 
including MART-1, gp100, tyrosinase, TRP-1 and TRP-2 (Boon and van der 
Brugges, 1996; Kawakami and Rosenberg, 1997; Kawakami, Dudley et al, 2001).  
Early immunotherapies for melanoma have taken advantage of these tumor 
specific T cell populations either by intrinsic expansion with administration of 
cytokines, vaccinations or by ex vivo expansion and adoptive transfer.  However, 
clinical efficacy has proven elusive.  Current therapeutic approaches have 
focused primarily on CD8+ cytotoxic T cells, which have limited durability and 
capability to recruit the other components of the immune response.  In particular, 
CD4+ T cells play a central role in a robust immune response including induction 
and maintenance of CD8+ T cells, activation of APCs, upregulation of MHC 
molecules, and in limited cases the direct lysis of tumor cells (Hock et al, 1991; 
Hung et al, 1998; Cohen et al, 2000; Pardoll and Topalian, 1998; Bennettet et al, 
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1998; Toes et al, 1998; Schoenberger et al, 1998; Gerloni and Zanetti, 2005; 
Williams et al, 2006; Kennedy and Celis, 2008).   
The promise of cancer immunotherapy is the permanent modification of 
the immune system to recognize tumor antigens.  A powerful tool in achieving 
this goal has been the development of gene therapy by viral vector delivery 
systems.  Recent clinical applications have shifted to lentiviral technology 
because of their safer integration profile and greater infectivity in mitotically 
quiescent cells.  Implementing a lentiviral construct, I was able to create a gene 
delivery system capable of efficiently and permanently alter the T cell repertoire 
to express a highly avid and function T cell receptor capable of recognizing and 
destroying melanoma tumor cells in recipient mice.   
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II. Research Goals 
 
Immunotherapeutic approaches to treat melanoma have become 
increasingly sophisticated with attempts to manipulate the immune response via 
high dose IL-2, adoptive transfer, and gene therapy.  Although, many of these 
approaches show promise, clinical response appears modest, with adoptive 
transfer of melanoma antigen specific CD8+ T cells showing the most impressive 
results.   CD8+ cytotoxic lymphocyte therapies are limited by lack of support from 
the remaining cellular components of the immune system such as dendritic cells, 
memory cells, B cells, and CD4+ T cells.  Increasing evidence indicates that 
CD4+ T helper cells play a crucial function as a facilitator in the anti-tumor 
response, particularly through the induction and maintenance of CD8+ T cell 
immunity (Ossendorp et al, 1998; Overwijk et al, 1999; Langlade-Demoyen et al, 
2003; Wang et al, 2004: Sun Et al, 2004; Williams et al, 2006).  Yet despite their 
important role there have been limited efforts to exploit CD4+ T cells to enhance 
the immune response to cancer.   
Based on the synthesis of the current research given above, the 
overarching goal of this research was to gain a better understanding of lentiviral 
transduction on hematopoietic stem cell transplantation, development and 
selection, and potential anti-tumor immunity of CD4+ T cells specific for 
melanocyte differentiating antigens.  In particular, I was interested in the kinetics 
of bone marrow transplantation in terms of engraftment, reconstitution and long-
term viability and function of gene modified CD4+ T cells specific for a naturally 
occurring self-antigen, TRP-1.  Furthermore, I was seeking to better understand 
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the role of central and peripheral selection in the proliferation and expansion of a 
tumor antigen/self-antigen specific CD4+ T cells in both the non-transplant and 
post-transplant setting.  Finally, we hoped to discover anti-tumor capacities of 
this novel TRP-1 specific T cell.   
To address this goal, I first identified, characterized, and isolated a TRP-1 
peptide specific TCR.  I then created a lentiviral delivery system optimized to 
transfer the TRP-1 TCR gene to hematopoietic stem cells.  In parallel, I created a 
novel TRP-1 TCR Tg mice expressing a chimeric TCR with our TRP-1 TCR 
variable region and a murine constant region.  I then conducted a series of 
primary and secondary bone marrow transplant experiments.  By analyzing the 
kinetics, expression, viability, and function of the transduced HSC population and 
its derivative cells I sought to identify the modalities for cancer immunotherapy 
that address some of the shortcomings of current clinical approaches.   
The overall strategy consisted of identification and isolation of a TRP-1 
specific TCR from a human peripheral blood mononuclear cell (PBMC) colony, 
construction of a lentiviral construct encoding the TRP-1 TCR, subsequent 
transduction of HSCs and bone marrow transplantation of gene modified 
hematopoietic stem cells into myelodepleted recipients.   I sought to address 
several basic questions regarding engraftment and development of gene 
modified HSCs in bone marrow transplants and to further investigate the anti-
tumor capacity of lentivirus transferred CD4+ T cells.  Initially, I investigated the 
kinetics of engraftment and development of lentivirus transduced HSCs in bone 
marrow transplants.  Secondly, I investigated the role of MHC molecules in 
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central and peripheral selection of a lentivirally delivered self-antigen specific 
TRP-1 TCR in the post transplant setting.  Finally, I sought to determine the 
functional capacity of TCR gene transferred CD4+ T cells to mediate 
autoimmunity and anti-tumor immunity.   
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III. Materials and Methods 
Animal and Cell Lines 
TRP-1 TCR Tg mice were generated in collaboration with the Restifo Lab at the 
National Cancer Institute at the NHI (Bethesda, MD).  The α and β genomic 
variable domains of the human TRP-1 TCR were PCR amplified from the same 
full length sequence (described below) and TA-cloned into pCR4TOPO 
(Invitrogen) validated by sequencing, sub-cloned into TCR cassette vectors 
provided by Dr. D. Mathis (Harvard Medical School, Boston, MA (Kouskoff et al, 
1995)).  The TRP-1 TCR cassette vectors were then sent to the Restifo Lab and 
co-injected into fertilized C57BL/6 embryos yielding 9 TCR transgenic founder 
lines. The founder mice were shipped to the Indiana University LARC animal 
facilities where the founder mice were screened by PCR for the presence of the 
transgene, and then crossed with themselves and with DR4 Tg mice to generate 
experimental colonies.  Progeny were screened for allelic copies of the TCR and 
DR4 genes by PCR, or by flow cytometry using a PE-labeled DR4 UltimerTM 
containing the TRP-1277-297 epitope (ProImmune Ltd, Oxford, UK).  Murine class 
II-deficient, DR4-IE transgenic mice (DR4 Tg) (Ito et al, 1996), fully backcrossed 
onto a C57BL/6, were purchased from Taconic Farms. B6.SJLPtprcaPepcb/BoyJ 
(or Boy-J) and NOD/SCID/IL2rγKO (NOD/SCID-2) mice were purchased from 
Jackson Labs.  All mice were 6-10 weeks old for experiments, and housed and 
bred at the IU LARC barrier facility under an established study. Murine tumor 
lines B16 (ATCC, Manassas, VA), MC-38 (ATCC); human melanoma lines 624 
and 1102 Mel, human EBV-B cell line 1088 EBV-B (provided by S.A. Rosenberg, 
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Surgery Branch, NCI/NIH), and human lymphoid cells line Sup-T1 (ATCC) were 
maintained in complete media (CM) (Touloukian et al, 2000).  The HLA-DRB1* 
genotypes of human tumor lines used in the following experiments included 624 
Mel (0401,0701); 1102 Mel (0401,1502), and 1088 EBV-B (0301,0401), 
(Toulokian et al, 2001).  Human melanoma line 1102 Mel was transduced with 
the retrovirus pLXSN (Clontech, Mountain View, CA) expressing either GFP or 
TRP-1 (provided by P. Robbins, Surgery Branch, NCI/NIH).  Murine tumors B16 
and MC-38 were transduced with a lentivirus expressing DRA and DRB1*040.  
DR4 expressing tumors were periodically enriched by flow sorting to maintain 
expression at >80%. 
Limiting Dilution 
T cell clones specific for melanocyte differentiating antigens were isolated 
using limiting dilution.  Human peripheral blood mononuclear cells harvested 
from HLA-DR4+ donors were harvested by pheresis and donated by the 
Rosenberg Lab (NCI/NIH).  PBMCs were plated in 96 well U-bottom culture 
plates at a concentration of 0.3 cells/well co-cultured with DR4+ 1088 EBV B cells 
pulsed with target peptides and cultured for 7 days.  The T cell clones were 
subsequently stimulated with allogeneic PBMCs from at least three different 
donors (5x104 cells/well) in human culture media  supplemented with IL-2 (50 
CU/ml) and OKT3 (30 ng/ml).  Cells were cultured from 7-14 days and screened 
for growth and antigen reactivity via ELISA for IL-2 and IFN-γ.  Selected clones 
were expanded using a previously described rapid expansion protocol in T25 
culture flasks with allogeneic PBMC (2.5x107 cells/flask supplemented with IL-2 
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50 CU/ml, and OKT3 30 ng/ml).  Clones expanded by rapid expansion were 
screened for target antigen specificity by ELISA with co-cultures for peptide, 
tumor lysates and whole tumor.   
Detection of Cytokines Using ELISA 
Purified peptides (HA306-318; PKYVKQNTLKLAT and human TRP-1277-297; 
ISPNSVFSQWRVVCDSLEDYD) were purchased from BioSource (Invitrogen, 
Carlsbad, CA. Monoclonal antibodies (mAbs) were used to block T cell 
interactions (at 50 µg/ml) and included: L243 (against HLA-DR; IgG2a; 
eBioscience, San Diego, CA), W6/32 (against HLA-A, B, C; IgG2a; eBioscience), 
L3T4 (against human CD4; IgG1; eBioscience), and HIT8a (against human CD8; 
IgG1; eBioscience).   Isolated T cells were washed and plated in triplicate on 
round bottom 96 well plates at a concentration of 105 cells/well.   T cells were 
stimulated with either medium alone or co-cultured with DR4+ 1088 EBV B cells 
alone, 1088 EBV B cells pulsed with human TRP-1 (amino acids 277-297), 
murine TRP-1 (amino acids 277-297) and 2H hTRP-1 (amino acids 266-477) 
proteins, a control OVA recombinant peptide all at a concentration of 50µg/ml, 
murine (B16-F10) and human (1088 and SK23 Mel) melanoma lysates, along 
with control 1088 EBV-B cell lysate, and DR4- B cells loaded with 1088 Mel 
lysate.  To up-regulate MHC class II, 624 Mel was pre-treated with IFN-γ x 48 hr 
at 200 U/ml).  All targets (105) and T cells (105) were cocultured in duplicates in 
U-bottom 96-well plates for 24 h.  Culture supernatants were assayed for IFN-
γ and IL-2, using commercially available ELISA kits (BD Bioscience, San Jose, 
CA).  In brief, 96 well immunosorbent plates were coated with IL-2 and IFN-γ 
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specific capture antibody plates for 12 hours at 4oC in a 2% BSA PBS assay 
diluent buffer.  Plates were subsequently washed three times in ELISA wash 
buffer (0.1% Tween-20 in PBS) and blocked for two hours at room temperature in 
assay diluent buffer.  Diluent buffer was removed and plates were loaded with 50 
µl of supernatants and cytokine standards and incubated for two hours at room 
temperature.  Plates were washed five times with wash buffer to remove excess 
supernatants and incubated at room temperature with 100 µl of biotinylated 
detection antibodies dissolved in assay diluent buffer for 1 hour.  Plates were 
washed five times with wash buffer and incubated with streptavidin alkaline 
phosphatase in diluent buffer for 1 hour.  The reactions were stopped with a 50 µl 
of stop buffer (2M hydrosulphuric acid) and the plates were read with 10 minutes 
of stopping the reactions.  Cytokine levels were determined by measuring the 
absorbance at 415 nm.  All assays were performed at least twice with similar 
experimental results. 
Cloning of TRP-1 TCR 
T cell clones specific and highly avid for TRP-1 were isolated by limiting 
dilution.  From these clones the gene for the TCR was sequenced using a 5’ 
rapid amplification of cDNA ends (RACE) assay kit (R&D Systems).  Total RNA 
was extracted from the T cell clone, and each TCR subunit was amplified. The 
PCR products were subsequently TA-cloned and sent to the NCI for sequencing 
to determine the variable regions of the α and β chains.  After determining the 
specific α and β chains, the full-length chain was amplified, TA-cloned, and 
resequenced yielding specific, fully amplified TCR chains.  The amplified TCR 
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chains were sent back to our laboratory wherethe genes were TA cloned using a 
TOPO TA cloning kit from Invitrogen.  The gene for the α and β chains were 
subsequently PCR cloned into an Invitrogen Gateway entry plasmid (pENTR) 
separated by either an internal ribosomal entry site (IRES) or a Furin self-
cleaving sequence (F2A).  The TCR alpha and beta chains were re-amplified 
with an optimal Kozak initiation sequence (Kozak, 2002) and restriction sites 
using Platinum-Pfx polymerase (Invitrogen).   To generate the IRES vector, the 
α-chain was cloned into an IRES-containing derivative of pENTR1a (Invitrogen) 
from DraI to a SpeI site 5’ to IRES.  The β-chain was cloned 3’ from an NcoI site 
at the 13th ATG of IRES to XbaI.  Both chains were then sequenced and LR-
clonased, into a modified Gateway (Invitrogen) destination lentiviral plasmid 
(pRRL-Dest-Wsin) (Dull et al, 1998).  These modifications included a central 
polypurine tract derived from HIV-pol(cPPT) sequence inserted between the REV 
response element (RRE), the CMV promoter, and the Woodchuck hepatitis virus 
posttranslational regulatory element (WPRE) element proximal to the 3’ SIN-LTR.  
To generate the F2A vector, Furin-2A peptide sequence was exchanged through 
a series of intermediates for the IRES element, transferred into the pENTR 
plasmid, then LR-cloned from the pENTR plasmid into pRRL-Dest-Wsin. 
Similarly constructed vectors which contain GFP (LV-GFP) and (LV-DR4) were 
also prepared. 
Other Plasmids Used 
Lentivirus component plasmids  and a lentivirus encoding for the green 
fluorescent protein (pCSCGW-GFP) were donated by the Cornetta Lab and 
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included packaging plasmid pMDLgpRRE (containing the gag-pol accessory 
genes), rev expressing plasmid pRSV-rev, and envelope plasmid pMDG-VSVG.  
Once again employing the Invitrogen Gateway System, our collaborators in the 
Cornetta Lab were able to construct a bicistronic lentiviral plasmid encoding for 
the α and β chains of the human HLA-DRA-DRB1*0401 MHC class II molecule 
(pCSCGW-DR4 IRES) using the same cloning methods described above.   
Lentiviral Production 
LV-GFP and LV-TRP1-IRES or LV-TRP1-F2A lentiviral supernatants were 
prepared by transient transfection of 293T cells in T-150 flasks with vector DNA 
(26.4 μg), packaging plasmid pMDLgpRRE (containing the gag-pol accessory 
genes) (13.2 μg), rev expressing plasmid pRSV-rev (6.6 μg), and envelope 
plasmid pMDG-VSVG (9.2 μg) using a Promega ProFection Mammalian 
Transfection System-Calcium Phosphate Kit. Culture medium was replaced 16-
18h after transfection with GIbco OptiPro SFM.  Viral supernatants were then 
harvested at 24 and 48 hours after media exchange, centrifuged at 3500 rpm, 
filtered through 0.45mm cellulose acetate filter, and concentrated with a 
CentriconPlus-70 device (Millipore) at 3500 rpm x 30 minutes. The concentrated 
viral supernatants were aliquoted and frozen at -80oC before calculation of titer. 
Lentivirus Titering 
To determine the titer of frozen viral supernatants, 293 cells were plated at 
105 cells/well in 6 well plates, and serial dilutions (10-3, 10-4, 10-5) of concentrated 
vector supernatants were prepared in DMEM media and incubated with cells for 
4 hours with polybrene at 8μg/ml (5% CO2, 37oC). Cells were maintained in 
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culture for 72 hours, trypsinized and aliquoted, stained with a PE conjugated 
TCR β-chain antibody, and analyzed by flow cytometry. Titers were calculated 
using the following formula: titer = (F x Co/V) x D. F is the frequency of GFP-
positive or TCR-β chain positive cells determined by flow cytometry; Co is the 
total number of target cells infected; V is the volume of the inoculum; D is the 
virus dilution factor.     
Collection of Bone Marrow, Peripheral Blood Cells, and Splenocytes 
Mice were euthanized by cervical dislocation and bone marrow cells were 
harvested by bilateral surgical resection of the tibia and femur.  Collected tibia 
and femur specimens were collected in RPMI complete media (5% FBS in RPMI 
1640 supplemented with 1% L-glutamine, 1% non-essential amino acids, 1% 
sodium pyruvate, 1% penicillin/streptomycin) to minimize cell death.  Harvested 
tibia and femurs were thoroughly removed of excess muscle and connective 
tissue.  Bone marrow was then washed out of the bones by insertion of a 27 
gauge syringe needle and flushing with RPMI complete media from both proximal 
and distal ends of the bones.  The crude bone marrow cell collection was then 
collected in 50 ml conical tubes and centrifuged at 1200 rpm and excess media 
discarded.  Erythrocytes were lysed using an RBC lysing buffer (Qiagen, Inc.) for 
10 minutes at room temperature.  The cells were then filtered through a 75 mm 
nylon filter to remove clumps and ensure a single cell solution.  The cells were 
centrifuged at 1200 rpm for 5 minutes and washed twice with appropriate media 
or buffer.  
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Peripheral blood cells were harvested by tail vein bleeds.  Mice were 
inserted into specially designed metal mouse holders which immobilized the mice 
while allowing access to the tails.  Using surgical scalpels, superficial incisions 
were made as distally as possible to nick the tail veins.  The tail veins were then 
bled by external manipulation and peripheral blood collected in heparin treated 
microcapillary tubes.  Collected peripheral blood was subsequently transferred to 
1ml of 2% heparin solution in flow cytometry tubes to prevent clotting.  Cells were 
then centrifuged and excess heparin discarded.  Peripheral blood cells were 
treated were RBC lysis buffer and filtered as described for bone marrow cells.  
Spleens were collected by surgical resection and homogenized by mechanical 
mastication with a sterile glass slide and a blunt instrument.  Crudely 
disaggregated splenocytes were then treated with RBC lysis buffer, filtered to 
yield a single cell suspension, and washed as previously described.   
Collection of Human Cord Blood Cells 
Cord blood cells were collected by fractionation using Ficoll gradient.  
Cord blood was graciously donated by the Broxmeyer Lab.  Only cord blood less 
than 24 hours old were used in these experiments.  The cord blood was mixed 
with an equal volume of EDTA Wash Buffer (2mM EDTA in PBS) solution to 
prevent clotting and lyse RBCs.  This cord blood mixture was carefully layered 
over 20 ml of Ficoll plaque in 20 ml aliquots in a 50 ml conical tube.  The tubes 
were then centrifuged at 1500 rpm for 30 minutes and the white cell layer formed 
between the Ficoll and aqueous layer was collected.  Collected cells were 
washed with 40 ml of EDTA Wash Buffer to remove excess Ficoll plaque and 
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centrifuged at 2000 rpm for 20 minutes.  Excess buffer was discarded and the 
remaining cord blood cells washed twice with appropriate media or buffer.   
Magnetic Bead Separation 
Murine bone marrow cells and human cord blood cells collected as 
previously described were treated with antibody labeled magnetic microbeads to 
extract murine Lin- cells and human CD34+ cells, respectively, using Miltenyi 
Biotec magnetic microbead separation kits (Miltenyi Biotec).  Cells were washed 
with MACS buffer (2% bovine serum albumin in PBS) and labeled with an 
appropriate amount of specific Biotin-Antibody Cocktail for 10 minutes at 4oC.  
The cells were than incubated with an anti-biotin microbead solution for an 
additional 20 minutes at 4oC.  The cells were washed with MACS buffer, 
centrifuged at 1200 rpm and excess buffer discarded.  Samples were then 
suspended in MACS buffer and run through a MACS column (LS column) and 
MACS separator (Miltenyi Biotec).  Collected cells were centrifuged, washed with 
MACS buffer and counted.  A small aliquot was set aside for antibody staining 
and analysis by flow cytometry to check the efficiency of separation and purity of 
the collected samples.  The remaining cells were cultured in the appropriated 
pre-stimulating media for 12 to 36 hours prior to lentiviral transduction.  Murine 
Lin- cells were prestimulated for 12 to 36 hrs in a murine prestimulating media 
(Gibco StemPro 34 SFM Media, 1% Penicillin/Streptomycin, 1% L-Glutamine, 
100 ng/ml SCF, 10 ng/ml TPO, 50 ng/ml Flt-3 Ligand).  Human CD34+ cells were 
prestimulated for 12 to 36 hrs in a human prestimulating media (Gibco StemPro 
34 SFM Media, 1% Penicillin/Streptomycin, 1% L-Glutamine, 100ng/ml SCF, 50 
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ng/ml TPO, 100 ng/ml IL-6).  Pre-stimulated cell populations were then 
transduced with lentivirus.  
Transduction Protocol 
Cells were collected and plated at 5x105 cells per well in 24 well flat 
bottom culture plates and incubated overnight in appropriate media.  Cells well 
centrifuged and excess media removed.  Cells were then spinoculated with 
concentrated lentiviral supernatant in appropriate media supplemented with 8 
µg/ml of polybrene at 1200 rpm for at least 2 hours at 25oC.  Spinoculated cells 
were immediately incubated for a further 2 hours at 37oC.  Following this 4 hour 
spinoculation/incubation period the cells were centrifuged at 1200 rpm for 5 
minutes and excess media was removed by aspiration.  All cells were transduced 
at multiplicity of infections ranging from 10:1 to 100:1 depending on the 
experiment.  Following remove of the viral supernatant/media fresh media 
appropriate for the cell type was added to the wells.  The transduced cells were 
incubated at 37oC for 72 hours.  Transduced cells were then either antibody 
stained for analysis by flow cytometry or prepared for bone marrow 
transplantation.   
Cell Staining and Analysis Using Flow Cytometry  
Isolated cells were placed in flow cytometry tubes and washed twice with 
FACS buffer (2% fetal bovine serum in PBS).  Following centrifugation at 1,200 
rpm for 5 minutes at 4oC, wash buffer was discarded and 1µl/tube of anti-mouse 
FcIII/II receptor antibody (Fc Block; BD Biosciences) was added to each tube and 
incubated for at least 15 minutes at 4oC.  When staining with the TRP-1 Ultimer 
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(ProImmune, Inc.), Ultimer was added (5 to 10 µl/tube depending on cell count), 
vortexed, and incubated in darkness at room temperature for 4 hours.  The cells 
were then washed twice with FACS buffer and excess wash buffer discarded.  
For antibody staining, specific flourochrome conjugated antibody was added (1 to 
10 µl depending on the antibody), vortexed, and incubated in darkness at 4oC for 
at least 30 minutes.  The cells were then washed twice with FACS buffer and 
excess buffer discarded.  If the analysis was to occur on the same day as 
collection and staining, samples were kept at 4oC in darkness until flow 
cytometric analysis.  If the analysis was to occur the following day or later, the 
cells were fixed by addition of a 2% formaldehyde in PBS fixation buffer (200 
µl/tube) and storage at 4oC in darkness.  Samples were analyzed by flow 
cytometry on FACScan, FACS Calibur, or LSR II machines and data was 
analyzed using BD CellQuest (BD Biosciences).  To determine gene specific T 
cell frequency a combination of antibodies against CD45 (FITC, eBioscience), 
CD45.1 (FITC, eBioscience, CD3 (PE Cy5, BD Bioscience), CD4 (APC, BD 
Bioscience), CD8 (Pacific Blue, eBioscience, and the DR4 UltimerTM containing 
either the TRP-1277-297 epitope (TRP1-Ultimer) or the control gp10044-59 epitope 
(both PE, ProImmune) were used.  To determine T cell activation status, a 
combination of antibodies against CD4 (APC), TRP1-Ultimer (PE), CD44 (PE 
Cy5, eBioscience), CD45RB (FITC, eBioscience), and CD62L (Pacific Blue, 
eBioscience) were used.  To determine the frequency of post-transplant human 
mononuclear cells following transplantation into NOD/SCID-2 mice, peripheral 
blood samples were stained with mCD45.2 (FITC, eBioscience), hCD45 (PE 
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Cy5, BD Bioscience), hCD4 (APC, BD Bioscience), hCD8 (Pacific Blue, 
eBioscience), and the TRP1-Ultimer (PE).  Statistical significance in gene 
expression between groups was determined using a Student T-test. 
Bone Marrow Transplantation 
Transduced cells were incubated for three days and subsequently 
collected, washed in PBS, and counted.  Recipient mice were placed on 
doxycycline feeds four days prior to transplantation and lethally irradiated (950 
rads) one day prior to transplantation.   Each mouse was administered 5x104 of 
either the LV-TCR transduced or TRP-1 TCR Tg Lin- bone marrow cells along 
with 5x105 either HLA-DR4 Tg or C57BL/6 competitor unfractionated bone 
marrow cells via tail vein injection.  The mice were carefully placed in 
immobilizing containers and using a 27 gauge needle, a syringe preloaded with 
the proper concentration of both the HSCs and the competitor rescue whole bone 
marrow cells was threaded into the lateral dorsal tail vein.    
Immunohistochemistry 
Skin or tumor samples were both fixed in formalin and embedded in 
paraffin or snap frozen in liquid nitrogen.  The fixed or frozen samples were sent 
to the Indiana University Pathology Laboratories where standard H&E staining 
was done on all specimens.  For skin samples, blocks were stained with S100 
(rabbit polyclonal 1:1000, Dako, Glostrup, Denmark; Envision Rabbit Polymer 
DAB), CD3 (rabbit polyclonal 1:200, Dako; Envision Rabbit Polymer DAB), or 
human- TCR-β (mouse IgG1 1:50, Santa Cruz Biotechnology, Santa Cruz, CA; 
Envision Rabbit Polymer DAB). Skin sample were also frozen in liquid nitrogen 
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and stained with antibodies to CD4 (RM4-5 1:500, Serotec, Oxford, UK; Donkey 
anti-Rat DAB) and CD8 (169.4 1:200, Serotec; Donkey anti-Rat DAB). For tumor 
samples, blocks were stained with CD3 (Envision Rabbit Polymer NovaRed), or 
human- TCR-β (Envision Rabbit Polymer NovaRed). 
Determination of LV-TCR Gene Expression  
Total RNA was isolated from 1x105 BM cells obtained from 6 month 
secondary transplant recipients (both LV-TCR and Control) and converted to 
cDNA. A qPCR analysis using ABI One-Step Real-Time PCR System (Applied 
Biosystems - ABS, Foster City, CA) was then performed using a custom 
designed α-variable-chain probe (ABS) specific for the LV-TRP-1 vector.  
Relative TCR gene expression (RQ) was based on the amplification ratio of LV-
TCR/Control Txp using β-actin as an endogenous control.  The PCR reactions 
were set up with TaqMan PCR Core Reagents (ABS) using about 100 ng of 
cDNA (50 µl total reaction volume), and amplified at 95°C for 10 minutes plus 40 
cycles of 95°C for 15 seconds and 60°C for 1 minute. 
Lentivirus Integration Analysis 
Genomic DNA (gDNA) was prepared (Qiagen, Valencia, CA) from 1x105 
BM cells obtained from 6 month secondary transplant recipients (both LV-TCR 
and Control). Concentration and purity of the gDNA was determined by 
spectrometry. All samples showed a 260/280 ratio of 1.7 or greater indicating a 
high purity.  Sample concentrations varied from 0.400 to 0.0500 mg/ml.  The 
gDNA from transplant recipients were diluted to a concentration of 250 ng/ml. 
The gDNA samples were then sent to the Cornetta Labe where the samples 
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were then individually digested with Tsp5091 (New England BioLabs Ipswich, 
MA) at 65°C for 2 hours.  Following digestion, gDNA fragments were purified 
using a MinElute Reaction Cleanup Kit (Qiagen).  In short, 150 uL of Elution 
Reaction Cleanup (ERC) Buffer was added to each sample and transferred to 
spin columns.  Columns were centrifuged for 1 minute at >10,000 x G and the 
pass-through was discarded.  750 mL of Buffer PE was added to each column 
and spun for 1 minute at > 10,000 x G.  Pass-through was discarded and the 
column was dried by spinning for 2 min. at 10,000 x G.  The purified DNA 
samples were eluted from the columns with 12 ml of EB buffer.  Primers specific 
for the LTR region of the lentiviral plasmid were biotinylated with native Pfu DNA 
polymerase (Invitrogen).  The primer extension products were subsequently 
purified using the ERC kit.  Microbeads with covalently attached streptavidin 
(Dynabeads M-280, Invitrogen) were washed and 40 ml of the bead slurry was 
added to each biotinylated primer.  Beads were subsequently washed and blunt 
end adaptors were ligated with T4 DNA ligase.  Integration sites were then 
identified by nested PCR: master mix consisting of 2 x Extensor HiFi PCR mix 
(Invitrogen) and gDNA fragments were aliquoted into 0.2 mL PCR reaction tubes.  
1 ml of the microbead-primer bead slurry was added and PCR amplified (94°C x 
2 min, 95°C x 15 sec, 60°C x 30 sec, 68°C x 2 min for 30 cycles; 68°C x 10 min, 
4°C x hold).  After the 1st round of nested PCR a 1:50 dilution was done from 
each PCR reaction tube and a 2nd round of nested PCR was performed.  Each 
PCR sample was analyzed by agarose gel electrophoresis. 
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Tumor Treatment Assays  
Six month old secondary DR4 Tg transplant recipients involving an 
experimental arm (LV-TCR-F2a) and a control arm were subcutaneously 
implanted with B16-DR4 melanoma cells (5x105 cell/200 ml HBSS) at 5 mice per 
group (2 groups).  Perpendicular tumor diameters were blindly recorded every 3 
days.  Mice were sacrificed at 20 days post-implantation and tumors were 
excised for IHC.  The statistical significance between groups was based on tumor 
size (using a Student T-test).  Experiments were performed twice in a blinded, 
randomized fashion with similar results. 
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IV. Results   
Identification of a TRP-1 Specific TCR 
Using a clonal population of CD4+ T cells specific for the TRP-1277-297 
epitope (Touloukian, et al 2002), the gene sequence of the individual α and β 
subunits of the TCR were identified from these lymphocytes via a 5’ RACE 
strategy at the NCI (Invitrogen GeneRacer Kit).  In short, total RNA was extracted 
from the T cell clone, and each TCR subunit was amplified. The PCR products 
were subsequently TA-cloned and sequenced to determine the variable regions 
of the α and β chains.  After determining the specific α and β chains, the full-
length chain was amplified, TA-cloned, and resequenced, yielding specific, fully 
amplified chains: TCR-α: Vα13-2*01, J22*01; TCR-β: V5.4*01, J1-1*01, D1*01. 
The VDJ regions were analyzed using the V-QUEST search engine from the 
IMGT web site (http://imgt.cines.fr/IMGT_vquest/vquest?livret=0&Option= 
humanTcR). (Figure 2) 
Construction of a Bicistronic Lentivirus 
Next, I constructed a bicistronic lentivirus containing the genes for the α 
and β subunits.  I chose to implement a bicistronic lentivirus to deliver the α and 
β chains of the TCR because the co-expression and successful pairing of the two 
chains is essential for the proper expression of the TCR.  Previous experiments 
have shown efficient transduction of hematopoietic stem cells with multicistronic 
viral systems (Cui et al, 2003; Yang et al, 2002; Yang and Baltimore, 2005; 
Morgan et al, 2006).  I ultimately chose to implement a lentiviral vector because 
of their reported advantage at transducing mitotically quiescent cells such as 
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HSCs and clinically safer genetic integration profile (Schroder et al, 2002; Wu et 
al, 2003).  Two approaches were used to link the two target genes together.  I 
constructed both an internal ribosomal entry site (IRES) and Furin self cleavage 
protein (F2A) bicistronic lentiviruses.  Schematic diagrams for our lentiviral 
constructs are shown in Figure 3.        
Efficiency of Transduction 
To evaluate the efficiency and functionality of TCR gene transfer, I tested 
the newly generated LV-TCRs (LV-TCR-IRES or LV-TCRF2A) on human PBMCs 
prestimulated with IL-7. I used a TRP-1277–297–specific PE-labeled pentamer 
(Ultimer; TRP-1 Ultimer) to measure specific cell surface expression, to avoid 
confusing true expression levels of the introduced α/β heterodimer with levels 
that result from mispairings with endogenous T cell α and β chains. As shown in 
Table 1, I observed statistically significant differences in TCR gene expression 
using the LV-TCR-F2A construct at increasing viral titers (37.5% vs. 56.4%; P = 
0.0008 at MOI 100). Both the IRES and F2A constructs efficiently transduced 
JRT3 cells and PBMCs.  However, transduction with the target TCR proved to be 
more efficient using the F2A construct in both JRT3 cells (p=0.022 at an MOI of 
10:1) and PBMCs (p=0.0008 at MOI of 100:1) particularly at higher MOIs (Figure 
4).  Thus, the remainder of the experiments focused on the F2A construct.   
I next tested the efficiency of the lentiviral construct to transduce both 
murine and human HSCs.  Murine HSCs were harvested from bone marrow and 
enriched by depletion of lineage positive cells using a Miltenyi Biotec Lineage 
Depletion Microbead Kit.  Murine HSCs were prestimulated for 12 to 36 hrs in a 
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prestimulating media (Gibco StemPro 34 SFM Media, 1% 
Penicillin/Streptomycin, 1% L-Glutamine, 100 ng/ml SCF, 10 ng/ml TPO, 50 
ng/ml Flt-3 Ligand).  Human HSCs were harvested from human cord blood.  
Following fractionation the cells were enriched using a Miltenyi Biotec CD34+ 
Microbead Kit. Human HSCs were prestimulated for 12 hrs in a prestimulating 
media (Gibco StemPro 34 SFM Media, 1% Penicillin/Streptomycin, 1% L-
Glutamine, 100ng/ml SCF, 50 ng/ml TPO, 100 ng/ml IL-6).  Following 
prestimulation HSCs were spinoculated with lentivirus at MOIs from 10:1 to 30:1 
with 8 µg/ml of polybrene at 1200 rpms at 25oC for 2 hrs.  The cells were then 
incubated for an additional 2 hrs at 370 C.  Following incubation, the media was 
changed for fresh prestimulating media and incubated for 72 hrs.   
Results as measured by flow cytometry using a peptide-antibody complex 
(TRP-1 Ultimer provided by ProImmune Inc.) showed approximately 10-50% 
transduction efficiency in human CD34+ cells and approximately 10-20% in 
murine Lin- cells at MOIs of 15:1 to 30:1 (Figure 5).  I conducted multiple repeat 
experiments with Lin- HSC enriched populations with lentivirus encoding green 
fluorescent protein (LV-GFP) as a control group (Figure 6).  Lin- cell transduction 
with the LV-TRP-1 TCR showed high expression at 28.7% ± 3.0 as measured by 
flow cytometry.  Overall, the results demonstrate a high level of expression of the 
complete TRP-1 TCR in transduced Lin- cells.   
Transduced Cells Retain Functionality of TCR 
To evaluate the in vitro functionality of the LV-TCR-F2A lentiviral 
construct, we transduced IL-7 prestimulated PBMCs at an MOI of 15.  After 
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overnight incubation, transduced PBMCs were co-cultured with DR4+ 1088 EVB 
B cells loaded with a panel of control and experimental peptides.  Transduced 
cells were found to recognize the specific TRP-1277-297 peptide, melanoma tumor 
lysates (B16), and TRP-1 positive tumor lines (B16-DR4, 624 Mel pretreated with 
IFN-γ, and 1102 Mel stably transduced with TRP-1) only in the context of the 
proper MHC class II HLA-DR4 restriction element as measured by specific IFN-γ 
production on ELISA (Figure 7).  No increase in IFN-γ was seen with the control 
peptide HA306-318, control lysate (TRP-1 negative 1102 melanoma tumor 
lysate), or control intact tumor (1102 melanoma tumor cells transduced with a 
vaccina virus encoding GFP).  Moreover, interactions with peptide pulsed targets 
were found to be both DR-restricted (blocked by L243) and CD4-specific 
(blocked by L3T4), but were not effected by control class I and CD8 specific 
antibodies. 
Development of a TRP-1 TCR Transgenic Mouse 
 To help evaluate the efficiency and effects of lentiviral transduction on 
HSC development our collaborators in the Restifo Lab created a transgenic 
mouse strain which constitutively expressed the same variable α and β genetic 
components as the LV-TCR (TRP-1 TCR Tg).  The variable regions of the α and 
β chain of the TRP-1 TCR were cloned into TCR cassette vectors which encoded 
the murine constant regions of the α and β chains.  Our collaborator Dr. Nicholas 
Restifo at the National Cancer Institute, injected the TCR cassette vector 
encoding this chimeric TRP-1 specific TCR into the embryos of fertilized C57BL/6 
mice.  The founder mice were screened by PCR for the transgene, specifically 
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the variable region of the α chain.  Initial characterization of the naïve TRP-1 
TCR Tg mice by flow cytometry showed very limited presence of TRP-1 TCR 
specific lymphocytes in the peripheral blood or spleen using the TRP-1 Ultimer. 
The low or absent levels of TRP-1 specific T cells in the periphery of TRP-1 Tg 
mice is not surprising given the lack of expression of the proper MHC Class II 
restriction element in this transgenic mice.  In the native TRP-1 Tg mice levels of 
Ultimer positivity was near that of negative controls and only 6.4% ± 1.0 of 
peripheral blood CD4+ T cells were specific for the TRP-1 Ultimer (Figure 8).  I 
subsequently bred the TRP-1 TCR Tg mice with the MHC Class II HLA-DR4 Tg 
mice to obtain the proper restriction element.  In this double transgenic mouse 
which expresses the proper MHC restriction element, peripheral blood antibody 
and Ultimer staining revealed that 79% ± 8.3 of all circulating CD4+ T cells are 
specific for the TRP-1 Ultimer (Figure 8).  Mice crossed onto a HLA-DR4 
background strongly expressed specific TCR (CD4+/Ultimer+, 79% ± 8.3), while 
those on a C57BL/6 background expressed low levels only (CD4+/Ultimer+, 6.4% 
± 1.0; P < 0.0001). These results strongly suggested the necessity of aproper 
restriction element (HLA-DR4) in positive T cell selection. To control for 
experimental specificity and background (< 1%), I used a Ultimer specific for a 
gp10044-59 DR4-restricted epitope. This multimeric antibody control was used for 
all subsequent flow cytometry analysis. 
Transplantation of Lentivirus Gene Modified HSCs 
 To better understand the cellular dynamics and kinetics of lentivirally 
transduced HSCs to home, engraft, and reconstitute the immune system 
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following transplantation I began a series of transplantation experiments.  I 
initially sought to understand the basic mechanics of transplantation with 
lentivirally manipulated HSCs by conducting a pilot lentiviral transplant 
experiment.  Using a lentiviral construct encoding a gene for green fluorescent 
protein (LV-GFP), I transduced Lin- HSCs from Boy/J donor mice.  2.5x104 
transduced Lin- cells were transplanted per mice along with 5x105 competitor 
rescue bone marrow from unmanipulated C57BL/6 mice into 30 C57BL/6 
recipients.  Five mice were subsequently euthanized and the peripheral blood, 
splenocytes, thymus, and bone marrow were analyzed by flow cytometry for 
CD3, CD4, CD8, CD45.1, CD45.2, and GFP expression (Figure 9).  
Transplanted, transduced Lin- cells maintain GFP expression in the peripheral 
blood (CD45.1+/GFP+), developing into a high percentage (over 20% by 12 
weeks post transplant) of mature T cells (TCR+/CD3+) and CD4+ T cells.  Gene 
modified cells are also present and remain stable within spleen, thymus, and 
bone marrow for up to 6 months post transplant.  Furthermore, transduced HSCs 
expressing GFP appear to undergo nor thymic development progressing from 
double positive thymocytes to single positive mature thymocytes.   
Lentiviral Transduction of HSCs Leads to Stable Long Term Integration 
 Several lentiviral protocols have already been described for gene transfer 
into transformed cells, lymphocytes, DCs, and HSCs (Cui et al, 2003; Cavalieri et 
al, 2003; Lizee et al, 2004; He et al, 2005; Mostoslavsky et al, 2005).  Although 
different heterologous promoters (PGK, CAG, EF1α, and CMV), vectors (both 
mono and bicistronic), pseudotyped envelopes, and inoculation protocols have 
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been used, the vast majority involve the use of cytokine prestimulation (Miyoshi, 
2004).  Because HSCs are relatively resistant to even high concentrations of 
lentiviral particles (Sutton et al, 1998) and susceptible to cell death following viral 
manipulation, I based the transduction protocol on both an overnight 
prestimulation with SCF, TPO and Flt-3L, a spin/rest inoculation at an MOI of 15, 
followed by an overnight recovery phase in cytokine media prior to 
transplantation (Barrette et al, 2000; Mostoslavsky et al, 2005). 
To quantify the engraftment potential, gene transfer efficiency, and long-
term stability of transduced HSC, I employed a standard CD45.1/CD45.2 
competitive isocongenic repopulation (Tao et al, 2007).  I initiated a series of 
transplant experiments into DR4 Tg and C57BL/6 mice to determine the 
engraftment efficiency of unmanipulated TRP-1 Tg HSCs and LV-TCR 
transduced Lin- HSCs.  To assess the impact of lentiviral transduction on the 
engraftment and development of HSCs we established a CD45.1/CD45.2 
competitive transplant experiment with either TCR Tg or LV-TCR transduced Lin- 
BoyJ (CD45.1) HSCs and DR4 Tg (CD45.2) competitor bone marrow cells.  Bone 
marrow was harvested from the femur and tibia bilaterally and treated with ACK 
lysing buffer to remove RBCs.  The cells were subsequently disaggregated into a 
single cell solution and filtered through a 100µm nylon filter.  The bone marrow 
cells were then depleted of lineage positive cells by using a Miltenyi Biotec 
Murine Lineage Depletion Microbead Kit.  BoyJ HSCs were prestimulated 
overnight in a prestimulation cytokine media, and transduced the following 
morning with a concentrated LV-TCR supranatant  at an MOI of 30 to 1.  
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Transduced cells were incubated for three days and subsequently collected, 
washed in PBS, and counted.  Ten DR4 Tg recipient mice and five C57BL/6 
recipient mice were placed on doxycycline feeds four days prior to 
transplantation and lethally irradiated (950 rads) one day prior to transplantation.   
Each mouse was administered 5x104 of either the LV-TCR transduced or TRP-1 
TCR Tg Lin- bone marrow cells along with 5x105 DR4 Tg competitor 
unfractionated bone marrow cells via tail vein injection.  Five DR4 Tg recipient 
mice received the LV-TCR transduced HSCs (LV-TCR/DR4).  Five DR4 Tg 
recipients were given HSCs from the TRP-1 TCR Tg donors (TCR Tg/DR4).  Five 
C57BL/6 mice were transplanted with LV-TCR transduced HSCs (LV-TCR/BL6).  
A control transplant group of 5 DR4 Tg mice were established which were 
administered bone marrow cells from a C57BL/6 mouse.  Peripheral blood was 
obtained at 1, 4, 6, and 9 month time points and stained for murine CD3, CD4, 
and CD8 along with the TRP-1 Ultimer complex.  By 4 months, immune 
reconstitution appears robust with successful repopulation of both CD8+ and 
CD4+ T cells.  Figure 10 shows a representative flow cytometry analysis, which 
schematically outlines our analysis.  Each mouse was analyzed, by gating initially 
around CD3+CD4+ cells.  The Ultimer positivity within this population of gated 
cells was then determined.  As can be seen in this example, a high percentage of 
circulating lymphocytes in both experimental transplant groups were positive for 
the specific TCR with 43.3% and 43.8% of mature CD3+/CD4+ lymphocytes 
exhibiting specificity for the TRP-1 Ultimer in the LV-TCR and TRP-1 Tg mice, 
respectively.   
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 I further analyzed the entire pool of circulating lymphocytes in the 
peripheral blood, to measure the percentage of all lymphocytes that were specific 
for the TRP-1 Ultimer (Figure 11).  At 1 month post-transplant, TRP-1 specific 
mature CD3+CD4+ T cells constituted less than 5% of all lymphocytes in all the 
transplant groups.  However, by 4 months post transplant, differences in 
CD3+CD4+ Ultimer+ populations were evident in the LV-TCR HSCs transplanted 
into DR4 Tg recipients (LV-TCR/DR4) versus those transplanted into the 
C57BL/6 recipient mice (LV-TCR/BL6) (15.8% ± 2 versus 8.2% ± 2, p<0.05).  
Statistically similar to the LV-TCR/DR4 group, 11.6% ± 2.5 of mature CD3+CD4+ 
lymphocytes from the TRP-1 TCR Tg HSCs transplanted into DR4 Tg recipients 
(TCR Tg/DR4) were specific for the TRP-1 TCR.   
As seen on Table 2, by 6 months post-transplant this difference in TRP-1 
TCR positivity between the LV-TCR/DR4 and LV-TCR/BL6 groups had narrowed 
and was no longer statistically significant (33% ± 4.6 vs 38% ± 7.5; P > 0.05).  All 
groups showed continued increases in TRP-1 TCR positive T cells in the mature 
T cell population.   TRP-1 TCR positivity in the peripheral mature CD3+CD4+ T 
cell populations was 33% ± 4.6 in the LV-TCR/DR4 transplants, 25% ± 4.7% in 
the LV-TCR/BL6 transplants, and 38% ± 7.5 in the TRP-1 Tg/DR4 transplants.   
 I subsequently performed two additional repeat competitive transplantation 
experiments with TRP-1 TCR lentivirus transduced HSCs and DR4 Tg recipient 
host mice (5 mice in each group) and performed similar peripheral blood and 
splenocytes analyses at various time points up to 12 months.  My results 
demonstrate that the unmanipulated TRP-1 Tg HSC transplants on average had 
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a higher level of TRP-1 Ultimer positivity, particularly after the 4 month time point 
in all cellular compartments analyzed as compared to the lentivirally transduced 
TCR transplants.  However, the LV-TCR transduced transplants demonstrated 
robust high level expression of the TRP-1 TCR up to 12 months post transplant.  
I also learned some valuable information regarding the timing of the emergence 
of lymphocytes into the periphery and the kinetics of reconstitution of the 
lymphocyte population in our TRP-1 TCR model.  Lymphocytes expressing the 
TRP-1 TCR first emerge into the periphery around 4-6 weeks post transplant and 
steadily increase.  I analyzed several different compartments within the 
peripheral mononuclear cell population including the total peripheral blood 
mononuclear cells, all CD3+ cells, and finally the mature CD3+CD4+ T cell 
population.  As a percentage of all cells in the peripheral blood, TRP-1 TCR 
positive cells steadily increased from about 2.5% at 2 months to 5% in 4 months 
for both the LV-TCR and the TRP-1 Tg transplants.  However, by 12 months,  the 
TRP-1 Tg transplants were significantly higher in the TRP-1 Ultimer positivity 
than the LV TCR transplants (8% ± 1.7 versus 22.6% ± 1.5; P = 0.001). (Figure 
12).     When analyzing only the CD3+ lymphocyte population, a similar pattern of 
emergence and steady expansion is seen in both the LV-TCR and TRP-1 Tg 
groups.  However, at all time points the TRP-1 Tg group exhibited significantly 
higher levels of TRP-1 TCR expression peaking at 12 months, 17.8% ± 2.3 
versus 36.7% ± 2.4; P = 0.006 (Figure 13).  Finally, I analyzed the mature 
CD3+CD4+ T cell population (Figure 14).  In this population, TRP-1 TCR 
expression peaked around 6 months at 75.4% for the TRP-1 Tg transplant and 
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48.1% in the LV-TCR transplants, and slightly decreased at 12 months.  Even at 
12 months post transplants, both groups maintained a high level of TRP-1 TCR 
express (65.2% ± 6.3 in the TRP-1 TCR group and 26.1% ± 2.4 in the LV-TCR 
group; P = 0.004).   
Transduced T Cells Undergo Development in the Thymus 
The vast majority of early lymphoid progenitors travel to the thymus and 
undergo a complex multi-step process of differentiation, proliferation, and 
repertoire selection (Walker and Abbas, 2002; Ohashi, 2003; Heinzel et al, 
2007).  Although much of this process occurs early in mammalian life, there also 
appears to be increasing clinical and experimental evidence that thymopoetic 
activity undergoes substantial re-amplification (or “thymic rebound”) well into late 
adult life (Hakim et al, 2005). These findings are particularly true in patients 
successfully treated for HIV or following chemotherapy-induced lymphopenia and 
subsequent transplantation (Sfikakis et al, 2005).  Given the results that both an 
appropriate restriction element (HLA-DR4) and co-receptor expression (CD4, not 
CD8) are critical for TCR expression, I sought to determine both the cellular 
density and compositional makeup of individual thymic subpopulations in 12 
month old post-transplant recipients (approximately 14 months old overall). 
 The thymus of lentivirus transplanted mice were collected and analyzed.  
The thymii were surgically removed, mechanically homogenized, filtered and 
stained with TRP-1 Ultimer and antibodies against CD3, CD4, CD8 and CD45.  
Despite the old age of the mice, a high percentage of TCR specific gene 
expression was observed in double negative (DN), double positive (DP), and 
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single positive (SP) populations, these findings appear consistent with continued 
HSC production and thymic replenishment of gene-specific T cell progenitors.  
Analysis by flow cytometry revealed TRP-1 TCR expression at all stages of 
thymocyte development from the immature DN to DP and SP state (Figure 15).  
At 12 months 36% of DN thymocytes, 45% of DP thymocytes, 18% of CD8+ 
thymocytes, and 13% of CD4+ thymocytes expressed the TRP-1 TCR (Figure 
16).  Also observed was a steep and significant drop off (DP 45% ± 7.3; SP CD4 
13% ± 3.1; P = 0.002) in TCR gene expression as thymocytes transitioned from 
DP to SP, results consistent with partial central elimination of auto-reactive TRP-
1277-297-specific DR4-restricted specific T cells.  Overall these findings appear 
in agreement with existing models of self-tolerance (Bouneaud et al, 2000; 
Gallegos and Bevan, 2004; Anderson et al, 2005), as well as those unique to 
TRP-1 in which higher avidity T cells are generated in mice genetically deficient 
in TRP-1 (Brandmaier et al, 2009).  
Transduced CD4+ T Cells Retain Specificity and Function 
 Splenocytes harvested from LV-TCR tranplants were tested ex vivo for 
specificity and function by ELISA measuring IFN-γ release.  Splenocytes were 
fractionated for CD4+ T cells by magnetic microbead separation as previousy 
described then co-cultured overnight with DR4+ 1088 EBV B cells preloaded with 
a panel of TRP-1 specific and non-specific peptides and tumor lysates (Table 3).  
CD4+ T cell populations showed dramatic release to cytokine in response to the 
TRP-1 peptide in a dose dependent manner.  Furthermore, these T cells 
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recognized 624 melanoma tumor lysate, but not 1102 melanoma lysate which 
does not express high levels of TRP-1.    
Development of Autoimmune Vitiligo 
 A result of the LV-TCR transduced HSC transplantation has been the 
development of spontaneous autoimmune vitiligo (Figure 17).  Between 8-16 
weeks post transplantation, LV-TCR mice were consistently found to develop 
progressive vitiligo (Table 4).  This pattern of depigmented skin bordered by 
areas with no apparent signs of pigment loss resembled vitiligo development in 
other models of TRP-1 autoreactivity (Overwijk et al, 1999; Bowne et al, 1999; 
Leitner et al, 2003; Muranksi et al, 2008), as well those observed in patients that 
have responded to IL-2 treatment (Rosenberg and White, 1996), or those treated 
with myeloablative chemotherapy and the adoptive transfer of TIL (Dudley et al, 
2002).  A high proportion of transplant recipients regardless of DR4 background 
developed vitiligo when transplanted with either the LV-TCR HSC (16 of 19 mice) 
or the TRP-1 TCR Tg HSC (26 of 37 mice) and the DR4 Tg competitor bone 
marrow regardless of recipient background, while none of the control transplants 
including those with the LV-GFP and went on to develop autoimmune vitiligo.  
The emergence of spontaneous vitiligo in the C57BL/6 recipient mice indicates 
that thymic expression of HLA-DR4 and positive selection in the thymus is not 
necessary for autoimmune vitiligo.  However, the lack of vitiligo in all mice 
receiving C57BL/6 competitor bone marrow indicates the necessity for a 
peripheral antigen presenting cell expressing the proper MHC restriction element.  
Similar vitiligo development was also observed in mice transplanted with HSCs 
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derived the TCR Tg, but none in the endogenous, non-transplanted TCR Tg 
(despite the higher gene-specific frequency), nor in those lacking expression of 
HLA DR4.  These results suggested that myelodepletion and transplantation 
combined with specific immune reconstitution (either from LV gene-modified or 
Tg HSCs in combination with HLA-DR4 expression) provided the appropriate 
conditions for the development of autoimmune vitiligo. 
 To address the pathogenesis of autoimmune vitiligo, I analyzed both 
paraffin embedded and liquid nitrogen frozen skin samples from LV-TCR and 
control transplants by immunohistochemistry (IHC).  A small patch of the skin 
sample was fixed in paraffin and stained for immunohistology using markers for 
CD3 and S-100 (a marker specific for neurocrest cells such as melanocytes).  
Sub-dermal hair follicle centered melanocytes were nearly completed obliterated 
with effacement of the normal architecture based on staining with H&E.  
Furthermore, affected skin samples demonstrated a dense increase in CD3+ T 
cell lymphocytic infiltration in the vitiliginous dermal space surrounding the hair 
follicles but not in the control mice (Figure 18).  Frozen sections of the vitiligo 
afflicted skin patches stained for CD4 and CD8 revealed that the lymphocytic 
infiltrate consisted of both CD8+ and CD4+ T cells (Figure 19).  To determine if 
TCR gene-specific T cells were invading the sub-dermal compartment, sections 
were stained with an exclusively human TCR β-chain specific antibody (Figure 
20).  As observed, staining was both identical in pattern and location with the 
CD3 staining and distribution.  To verify antibody specificity, human tonsil and 
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mouse spleen samples were similarly analyzed and found to be appropriately 
positive and negative.     
Activation Status and Functionality of Transplanted T Cells 
 To further understand the pathogenesis behind post-transplant vitiligo, I 
investigated the activation status of TCR-specific CD4+ T cells.  I had already 
observed that non-transplanted endogenous TCR Tg mice failed to develop 
vitiligo. Based on these early observations, I hypothesized that post-transplant 
specific T cells would exhibit surface bound phenotypic features consistent with 
spontaneous immune activation (Dutton et al, 1998; Klebanoff et al, 2005; Yang 
et al, 2006; Stockinger et al, 2006).  To capture the phenotype of the TRP-1 TCR 
expressing CD4+ T cells, I collected splenocytes from 6 month old transplanted 
mice and separated CD4+ T cells using a no touch murine CD4+ magnetic 
Microbead separation kit (Miltenyi Biotec).  The CD4+ T cells were then stained 
with the TRP-1 Ultimer and antibodies for CD4, CD44, CD45RB, and CD62L and 
analyzed by flow cytometry.  Untreated, unmanipulated age matched DR4 Tg 
mice splenocytes were used as a control group.  In the native DR4 Tg control 
group, the CD4+ T cell population was CD44low, CD45RBhigh, and CD62Lhigh 
indicative of a naïve phenotype.   By comparison, the control transplant group 
exhibited a more generalized effector phenotype with CD44high, CD45RBhigh, 
CD62Lint activation profile.  In contrast, the activation profile of CD4+/Ultimer+ T 
cells from LV-TCR transplants was CD44high, CD45RBlow, and CD62Llow 
indicative of a T effector memory phenotype (TEM).  Importantly, the 
CD4+/Ultimer- subpopulation was similar in its expression profile to that of the 
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control transplant population (CD44high, CD45RBhigh, CD62Lint), suggesting the 
divergence of two distinct T cell populations within the same host, the clonal-like 
TEM CD4+/Ultimer+ vs. the polyclonal effector CD4+/Ultimer-, independent of the 
effects of transplantation (Figure 21).   
Given the spontaneous TEM-status of CD4+/Ultimer+ cells, I then 
addressed whether or not T cells from LV-TCR transplants, would immediately 
react to TRP-1 specific targets.  To test this question, splenocytes from 6 month 
old transplants (both LV-TCR and control) were harvested then stimulated ex 
vivo for 24 hours with peptide or tumor.  As seen Figure 22, cells obtained from 
the LV-TCR group responded to TRP-1 specific targets, secreting IFN-γ in 
response to TRP-1277-297 at titering peptide concentrations and to B16-DR4 
tumor, but not to control targets HA306-318 or to control tumor MC38-DR4 tumor.  
These results appear consistent with a specific and high avidity (recognition was 
observed at 1 nM) TH1-polarized T cell population. 
Secondary Transplant Experiments and Integration Analysis 
 Following the successful primary transplantation of LV-TCR transduced 
HSCs, I performed three secondary transplant experiments using the bone 
marrow from the primary transplants.  Bone marrow was harvested from the 
donor mice at the time of euthanization, in the LV-TCR transplant experiments as 
previously described.  5x105 whole bone marrow cells were non-competitively 
transplanted per mouse into DR4 Tg mice (5 mice per group).  Since these mice 
had previously received DR4 Tg competitor rescue bone marrow, a second 
competitive reconstitution was deemed unnecessary.  All mice were followed and 
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analyzed at 6 months post transplant for CD3, CD4, CD8, CD45 and TRP-1 TCR 
expression (Figure 23).  As shown, the levels of CD4+ T cells expressing the 
TRP-1 TCR closely matched that of the primary transplants and remained stable 
for the duration of the analysis.  TCR specific cells were identified at a level of 
47.5% ± 8.3 (CD45+/CD3+/Ultimer+) within the global CD3 compartment and at a 
level of 53.1% ± 10.7 within the CD4 sub-compartment (CD45+/CD3+/CD4+/ 
Ultimer+).  These results were notable for the higher expression levels observed 
within both populations compared with the 12 month expression levels observed 
in the parental primary transplant group (12 m primary vs. 6 m secondary, P = 
0.02).   
Having now demonstrated stable and high level TCR gene expression 18 
months after a primary transplantation, I sought to further understand the genetic 
stability of the 6 month old secondary transplant recipients.  Total RNA and 
gDNA was prepared from 1x105 BM cells (from both LV-TCR and control 
transplants) and analyzed by both qPCR for relative TCR gene expression and 
by standard PCR using a vector specific probe to determine the number of 
lentiviral integrants.  As seen in Figure 24A, using a probe specific for the 
variable chain of the humanized α subunit, TCR gene expression from LV-TCR 
transplants was found to be more than 1000-times greater than the background 
signal produced in control transplants but 43-fold less than that observed in the 
TCR-Tg group (P = 0.01 for LV-TCR vs. TCR-Tg).  These results were consistent 
with differences in protein level TCR expression. Using a probe specific for the 
LV vector backbone, 4-6 integration sites and internal control fragment were 
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identified by nested PCR in 3 separate LV-TCR transplant samples, compared 
with control transplant (0 integrants) (Figure 24B). Both results clearly 
demonstrate long-term post transplantation genetic integration and stability. 
Secondary LV-TCR Transplants Reject Subcutaneous Tumors 
Immune reconstitutions after BM transplantation, dendritic cell vaccination, 
or following the adoptive transfer of antigen-specific lymphocytes have been 
shown to enhance anti-tumor immune responses (Borrello et al, 2000; Gattinoni 
et al, 2005; Moyer et al, 2006).  Given the high level TCR gene expression, 
spontaneous autoimmunity, TEM activation, and in vitro anti-tumor activity, I asked 
if long-term secondary transplant recipients would induce protective tumor 
immunity.  To address this question, transplant recipients (both LV-TCR and 
control, 5 mice per group) were subcutaneously injected with B16-DR4 tumor 
cells. Because of the preexisting “activated” TEM status of the transplanted 
animals no additional cytokines, immune modulators (such as α-CTLA-4) or 
vaccinations were added to enhance the anti-tumor effect.  Beginning three days 
after injection, and every 3 days thereafter, the product of the perpendicular 
tumor diameters were recorded.  As seen in Figure 25, secondary LV-TCR 
transplants significantly rejected tumor growth compared with control transplants 
over a 20 day time period.  Tumor size between d12-d20 in the LV-TCR arm was 
also non-significant (P = 0.09) suggesting cessation of tumor growth.  
Based on IHC staining of paraffin-embedded specimens, tumors from LV-
TCR transplants but not controls were found almost entirely necrotic and 
associated with hemorrhagic infiltrates (Figure 26).  Tumors were also found to 
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contain dense trafficking populations of CD3+ and human TCR-β+ (gene-specific) 
tumor-infiltrating lymphocytes (Figure 26), suggesting a similar infiltrative pattern 
as that observed within the autoreactive vitiligo skin specimens.  The nova-red 
substrate was used instead of DAB to more effectively differentiate between 
necrotic tumor/pigment and the cellular infiltrate. 
Gene Modification and Transplantation of Human HSCs 
 Running in parallel with the murine HSC transplant studies I conducted a 
series of transplant experiments to elucidate the characteristics and kinetics of 
human CD34+ HSCs in non-obese diabetic/severe combined immunodeficient IL-
2 receptor γ chain knock out (NOD/SCID-2) mice.  CD34+ HSCs were extracted 
from fresh cord blood by fractionation as described in Materials and Methods.  
In brief, fresh cord blood (less than 24 hours old) was treated with an equal 
volume of 2mM EDTA in PBS solution.  20ml aliquots of the cord 
blood/EDTA/PBS mixture were carefully layered on top of 20 ml of Ficoll plaque 
in 50 ml conical tubes.  The cord blood was centrifuged at 1500 rpm for 30 
minutes to fractionate the lymphocyte layer.  The cell layer was collected and 
washed with 30 mls of the 2mM EDTA/PBS solution and centrifuged at 2000 rpm 
for 20 mins at 25oC.  The supernatant was discarded leaving behind the 
mononuclear cells.  The CD34+ cells were enriched for using a Miltenyi Biotec 
CD34+ Microbead magnetic bead separation kit.  Following selection of CD34+ 
cells, the CD34+ HSCs were incubated overnight at 5x105 cells per well in 6 well 
plates with human prestimulation media (StemPro SFM34 Media, 1% L-
glutamine, 1% penicillin/ streptomycin, 10ng/ml SCF, 100ng/ml TPO, 100ng/ml 
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IL-6).  The following morning the cells were transduced using our established 
transduction protocol with the TRP-1 TCR lentivirus.  Three days post-
transduction, the cells were collected and a sample of the transduced CD34+ 
cells was analyzed by flow cytometry using a CD34 antibody and the TRP-1 
Ultimer.  After confirmation of successful transduction, the transduced CD34+ 
cells were transplanted into previously irradiated (350 rads) NOD/SCID-2 mice at 
a concentration of 2.5x104 cells/mice along with 2.5x105 DR4Tg BM cells.  
Peripheral blood lymphocytes were analyzed by flow cytometry with antibodies 
for human CD45, CD3, CD4, CD8, HLA-DR, murine CD45.2 and the TRP-1 
Ultimer at set intervals up to 6 months post transplant.  
 Human lymphocytes were isolated by magnetic microbead separation for 
CD45 (Miltenyi Biotec) and analyzed for TRP-1 TCR expression.  At 3 months 
post transplant, I initially observed a higher than normal number of double 
positive immature T lymphocytes in the peripheral blood (Figure 27).  These 
double positive lymphocytes exhibited high levels of TRP-1 TCR expression 
(78%).  By 4 months post transplant, the number of double positive T cells had 
drastically decreased to 2% of all CD4+ T cells (Figure 28).  At 4 months, 10.3% 
of all mature single positive CD3+CD4+ T cells expressed TRP-1 TCR as 
measured by Ultimer staining and flow cytometry.   
TRP-1 TCR Confers Tumor Immunity 
Five of the NOD/SCID-2 mice transplanted with LV-TCR modified HSCs 
were enlisted in a tumor rejection assay.  A human melanoma line that had 
previously been transduced with a retrovirus encoding the gene for the MHC 
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class II transcription factor CIITA, 624 Mel CIITA was injected subcutaneously 
into the transplanted mice and 5 control NOD/SCID-2 mice.  The engraftment 
and growth of the melanoma was carefully monitored and measured for 24 days 
post injection (Figure 29).  As observed, none of the LV-TCR transplants 
developed measurable tumors.  However, all of the control transplants allowed 
for the engraftment and growth of the melanoma.  Tumors first became apparent 
in the control transplants at day 9 and continued to steadily grow up to 24 days 
post transplant.  
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V. Discussion 
While most gene-therapy strategies have focused on the introduction of 
defective genes or antigens or used fluorescent gene products to track long-term 
development, few have attempted to introduce TCR genes into HSCs (Dudley et 
al, 2000).  In those examples that do exist, TCR genes introduced with RVs have 
targeted only experimental antigens (OVA) (Morgan et al, 2003; Zhao et al, 
2005). Herein, I report a new translational model of TCR-based immunotherapy 
directly applicable to patients with metastatic melanoma. I demonstrate both 
spontaneous autoimmunity and the destruction of subcutaneous melanoma that 
occur following long-term transplantation with gene-modified HSCs.  My studies, 
based on the use of a high expression lentiviral system to deliver to HSCs a 
potent class II-restricted CD4+ TCR, were assisted by neither the use of 
vaccines, cytokines, or immune modulators to either induce a population of 
autoreactive memory T cells or to achieve its antitumor effects. 
To design a model encompassing features that would address both self-
tolerance and tumor immunity and simultaneously serve as a potential source of 
preclinical information, I utilized a previously identified tumor-reactive, self-
reactive, TRP-1-specific, DR4-restricted T cell clone.  I then engineered both a 
high expression LV and a TCR Tg expressing the same TCR genes.  As 
mentioned earlier, I focused on current generation SIN lentivectors, not only 
because of their enhanced capacity to stably infect metabolically dormant HSCs, 
but because of their improved biosafety profile compared with standard γ-RVs 
(Sinn et al, 2005; Levine et al, 2006).  These experimental observations have 
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been further supported by clinical trials either ongoing or those in preparation for 
treatment of patients with HIV, β-thalassemia, Parkinson’s disease, and Wiskott-
Aldrich syndrome (Hargrove et al, 2008; Isacson and Kordower, 2008; Galy et al, 
2008; D’Costa et al, 2009).  With a functional LV-TCR and TCR Tg in hand, we 
demonstrate engraftment, thymic trafficking and differentiation, long-term TCR 
gene expression in both murine and humanized transplants, spontaneous post-
transplant autoimmunity, and hemorrhagic necrosis of subcutaneous melanoma.  
Although experimental answers obtained from well-constructed transgenic 
models are largely precise and elucidating, they are also fraught with the 
potential for over-simplicity and a failure to translate into beneficial human 
medical care (Rivera and Tessarollo, 2008).  In this model, I used the TCR Tg 
solely to gauge the efficiency of gene-transfer.  The information gleaned from the 
TCR Tg was, therefore, designed to be in service to the greater translational 
value served by the LV-TCR.   
Using these building blocks I propose a novel melanoma based murine 
model to examine the role of CD4+ T cells in cancer immunology using a lentiviral 
delivery system to modify hematopoietic stem cells.  The model involves four key 
components: 1) isolation of a T cell receptor reactive to a specific melanocyte 
differentiation antigen, tyrosinase related protein 1 (TRP-1); 2) development of a 
lentiviral construct for the delivery of the gene encoding the TRP-1 TCR; 3) 
creation of a constitutively TRP-1 TCR expressing transgenic mouse (TRP-1 
TCR Tg) to study gene transfer efficiency; 4) transplantation of gene modified 
HSCs.   
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Effects of Lentiviral Transduction on HSC Transplantation  
Through the transplantation experiments I was able to elucidate the 
kinetics of transplantation following manipulation of HSC with lentiviral 
constructs.  Lentiviral transduction, although a traumatic and toxic event appears 
to have little or no deleterious effects on the ability of HSCs to home, engraft and 
reconstitute a lethally irradiated recipient.  The initial experiments with lentivirus 
encoding GFP allowed me to approximate the kinetics of transplantation and 
effectively set the stage for the larger, more ambitious LV-TRP-1 TCR 
experiments.   The general kinetics of transplantation of gene modified HSCs 
were consistent across all of the transplantation experiments.  Early peripheral 
blood mononuclear cells began emerging from the bone marrow at around 6-8 
weeks post transplant (Figure 8, 9 and 11).  Total cell number increases 
dramatically from 2 months to 4 months, then levels off until it reaches a steady 
state around 6 months post transplant.  These time points are mirrored in both 
the lentivirus transduced transplants and the unmanipulated TRP-1 Tg 
transplants (Figure 11) indicating that lentiviral transduction did little harm to the 
capacity of the HSCs to home, engraft and differentiated into blood component 
cells.   
A permanently reconfigured immune system of durable high-frequency 
lymphocytes has long been a goal of immunologists and clinicians in pursuit of 
treatments for viral pathogens and cancer (Parish, 2003).  Concerns persist, 
however, regarding the feasibility of delivering such a treatment within a narrow 
enough time-frame.  Most clinical therapies and translational models have 
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focused on fully actualized therapies that deliver their effect with little delay, such 
as vaccines (peptide, virus, DCs, heat shock proteins, gene-modified tumor 
cells), cytokine infusions (IL-2, IL-7, IL-12, GM-CSF), immune modulators 
(myeloablative chemotherapy, anti-CTLA-4) or adoptive immunotherapies (TIL, 
cloned T cells, gene-modified T cells) (Parish, 2003; Rosenberg, 2004).  
Limitations and delays in immune reconstitution are a well described physiologic 
consequence of autologous HSC transfer, and the kinetics of individual 
mononuclear populations have been shown to favor the early return of 
granulocytes and B cells, with CD4+ T cells often being the last subpopulation to 
return to normal levels (Talmadge et al, 1997; Laurenti et al, 2004).  In this 
model, such observations were also found to be true.  To improve T cell 
recovery, IL-7 administration has been successfully used in non-human primates 
(Storek et al, 2003) and patients in with cancer (Rosenberg et al, 2006).  
Nevertheless, the Achilles heel of such a potential treatment in patients pertains 
to the relative late emergence of the CD4+ T cell subpopulation.  Despite these 
concerns, the timing of maximum (or even normal) T cell recovery may not be the 
most meaningful physiologic end point of gene-modified HSC transfer.  Although 
gene-specific T cells peaked 4-6 months after transplantation, low levels were 
detected after 6-8 weeks and chronologically correlated with the development of 
vitiligo (occurring between 8-12 weeks).  These findings suggested that the 
magnitude of the TCR-specific frequency was less an important indicator of 
functionality than their qualitative behavior or the amplitude of their emergence 
into the periphery.  Such observations have been supported by other models in 
      62
which small numbers of T cell clones differing only by activation status or T 
helper phenotype more effectively induce autoimmunity when compared with 
control populations (Lanzavscchia and Sallusto, 2002; Minang et al, 2010).   
Given the lack of information pertaining to the kinetics of engraftment and 
development of lentivirus transduced HSCs, I was able to address several critical 
questions regarding the use of lentivirally transduced HSCs in bone marrow 
transplantation.  These experiments indicate that the time from transplantation, 
engraftment, and emergence from the bone marrow and thymus to the periphery 
for lymphocytes is around 6-8 weeks.  Furthermore, lymphocyte reconstitution 
happens briskly between 2-6 months then stabilizes after the 6 month time point 
and decreases slightly, but remains relatively stable for the duration of the 
experiments up to 12 months in almost all transplanted groups.    
Peripheral Homeostatic Proliferation Leads to Expansion of Selective T Cell 
Clones 
Homeostatic proliferation (HP) represents a naturally occurring multi-log 
expansion of lymphocytes in response to depletion or ablation followed by either 
BM reconstitution or adoptive transfer (Mackall et al, 1997; King et al, 2004).  
Immune responses that occur during HP appear to favor the dramatic expansion 
of T cells and lead to the precipitation of autoimmune events (King et al, 2004; 
Kruprica et al, 2006). These observations have been shown associated with a 
number of factors, including the increased availability of homeostatic cytokines 
(IL-7, IL-15), the depletion or inhibition or Tregs, generalized host inflammation, 
and the availability of self-ligands (Mackall et al, 1997; Fry et al, 2001; Boyman et 
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al, 2007).  IL-7 availability, in particular, has also been found to be a critical factor 
in T helper and thymocyte survival along with the promoting of HP of both naïve 
and memory T cell subpopulations (Fry et al, 2001).  
There are a number of possible explanations for the HP of TCR-specific 
CD4+ T cells.  Even though the importance of IL-7 has been clearly stated, I 
found that IL-7 receptor expression by flow cytometry on thymic DPs and SP 
CD4s as well as peripheral blood and splenic CD4s to be statistically no different 
within either the Ultimer+ and Ultimer- population.  On the other hand, although 
generalized antigen may be limiting to the vast majority of T cells, TRP-1 loaded 
DCs may be uniquely available to the CD4+/Ultimer+ subpopulation.  Unlike most 
antigens, a fragment of the TRP-1 protein (the highest expressed of all 
melanocyte differentiation antigens) containing the 277-297 epitope has been 
shown to be secreted into the peripheral circulation (Xu et al, 1997).  In theory, 
circulating TRP-1 could be captured by immature APCs (either in the skin or 
within peripheral lymphoid organs), that in turn become activated during the 
course of systemic injury from lethal irradiation (Hill et al, 1997; Zhang et al, 
2002).  Expansion of CD4+ T cells has been tied to not only the relative load of 
antigen, but to the prolongation of that antigen load well after initial exposure 
(Obst et al, 2005; Jelley-Gibbs et al, 2005).  With all this being said, the 
magnitude of the burst size may be a simple function of mass effect given the 
high frequency of gene specific HSCs and T cell progenitors introduced at the 
time of primary transplantation.  Lin– HSCs examined by flow cytometry 3 days 
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after transduction had TCR-specific levels that ranged between 35-70% (data not 
shown). 
Other explanations may also account for both the magnitude of the burst 
size and the unique TEM status of the CD4+/Ultimer+ subpopulation. In general, 
two competing models of memory T cell development have been proposed. The 
first involving a separate lineage from effectors, and the second proposing that T 
cells pass initially through an effector stage (Hu et al, 2001; Opferman et al, 
1999).  As a consequence of either scenario, T cell clones can then give rise to 
multiple effector and memory T cell populations, by means of asymmetrical cell 
division.  After antigen exposure, memory cell expansion is classically followed 
by contraction, and stable persistence.  Although I showed activation status at 6 
months post primary transplantation (similar profiles were found at all time 
points), I found a sharp increase in the total CD4+/Ultimer+ T cell population 
between the 12 month primary and 6 months secondary transplants, consistent 
with both memory decay and re-expansion.  I also found a splitting of two distinct 
T cell populations within the same host (the clonal-like TEM CD4+/Ultimer+ vs. the 
polyclonal effector CD4+/Ultimer-) irrespective of the effects of transplantation.  In 
the end, the CD4+/Ultimer+ T cell population may have had a competitive survival 
advantage and propensity for memory differentiation based on the relative high 
availability of TRP-1. 
Transplantation of LV-TCR Transduced HSCs Breaks Self-Tolerance 
The proposed TRP-1 TCR model allows for the novel study of a self-
antigen specific TCR in the post-transplant setting.   Although researchers in the 
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past have successfully transduced HSCs using viral systems none have explicitly 
characterized the fate of HSCs modified to express an endogenous self-antigen 
specific TCR.   Dr. David Baltimore and colleagues transduced HSCs to express 
an OVA specific CD4+ TCR.  However, because of the highly immunogenic non-
self nature of the antigen chosen it left unclear the effects of thymic selection on 
a normally occurring self antigen specific TCR such as TRP-1 (Yang and 
Baltimore, 2005).  As noted in the Results, engraftment and development of 
HSCs transduced with LV-TCR appeared robust up to 12 months post 
transplantation with only slightly reduced numbers of circulating TCR specific T 
cells in transplants without the expression of the proper MHC Class II restriction 
element in the thymus (Figure 9).  Initially, the LV-TCR/BL6 transplant group 
lagged behind the LV-TCR/DR4 transplants in terms of CD4+ T cell expression of 
TRP-1 TCR. The lag in TRP-1 TCR positive T cells in the LV-TCR/BL6 group is 
not altogether surprising given the lack of expression of HLA-DR4 in the thymic 
epithelium of C57BL/6 mice.  As we saw previously (Figure 7), in the non-
transplanted native setting, TRP-1 TCR Tg mice on a C57BL/6 background 
exhibit little to no T cells in the peripheral with TRP-1 TCR expression.  However, 
in the post-transplant setting a far higher number of TRP-1 specific T cells are 
found in the periphery.  By 6 months, there is statistically no difference in TRP-1 
TCR expression in the DR4 Tg and C57BL/6 recipients.  Most likely, the initial 
depression in TRP-1 specific T cells in the C57BL6 transplants is due to central 
deletion.  The lack of the proper HLA-DR4 restriction molecule in these recipient 
mice in conjunction with the expression of a self-antigen specific TCR leads to 
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the apoptosis and deletion of the T cell.  However, some TRP-1 TCR expressing 
T cells do escape deletion and appear in the periphery as detected by flow 
cytometry.  Considering that the sheer number of lymphocytes expressing the 
TRP-1 TCR has been artificially increased many fold higher than any naturally 
occurring TCR by gene modification, it is easy to imagine that the normal thymic 
deletion mechanisms might become overwhelmed.  Once, these self-antigen 
specific T cells escape into the periphery, they would be confronted with a 
microenvironment rich in homeostatic cytokines due to irradiation of the recipient 
mice and subsequent elimination of competing lymphocytes.  Further, these self-
antigen specific T cells would encounter antigen presenting cells loaded with the 
TRP-1 antigen.  In such a favorable stimulation- rich environment, the TRP-1 T 
cells could readily expand to fill the empty niche.  This homeostatic and antigen 
driven peripheral expansion would readily explain the transplantation kinetics I 
have observed in the transplant experiments.   
In TRP-1 model, vitiligo developed in C57BL/6 recipients (along with a 
corresponding similar level of TCR specific cells Table 3), not just in DR4 Tg 
recipients.  These findings underscore a broader range of effects by the gene-
specific CD4+ T cell population, regardless of the relative magnitude of circulating 
cells present.  The polarized TH1 production of IFN-γ may have produced multiple 
effects, including direct melanocyte cytotoxicity, up-regulation of MHC molecules 
that enhance target recognition, and an enhancement of APC activation leading 
to further amplification of the T helper response.  Such functions have been well 
associated with the unique, but underutilized properties of CD4+ T cells.  While 
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long-term cellular persistence was an initial objective of this model, the amplitude 
of gene-specific T cell expansion (between 8-24 weeks) and TEM activation were 
clearly dramatic, and we propose associated with both autoimmunity and 
antitumor activity.   
These transplant experiments hint that in the myelodepleted irradiated 
state engraftment and selection of TRP-1 specific CD4+ T cells does occur as 
indicated by the observance of spontaneous autoimmune vitiligo in these HLA-
DR4 negative recipient mice.  I thus, hypothesize that although central selection 
in the thymus may be a significant factor in maximizing the selection of TRP-1 
TCR specific CD4+ T cells, mechanisms of selection and homeostatic 
proliferation exist that either bypass or overwhelm the normal selection of T cells 
in the thymus.   
Conclusion 
These results highlight several important findings regarding reconstitution 
of the hematopoietic cells in the post transplant setting: 1) the expression of the 
proper MHC Class II restriction element, HLA-DR4, in the thymic epithelium may 
be necessary for the maximal central selection of T cells.  However, peripheral 
homeostatic expansion of peripheral lymphocytes in the context of HLA-DR4 can 
compensate for central deletion, 2) the LV-TCR transduced HSCs competed, 
engrafted, and developed comparably to the unmanipulated TCR Tg HSCs 
indicating that lentiviral transduction did not adversely affect the capacity and 
function of the HSCs, 3) the lentiviral gene delivery system successfully led to a 
high level of circulating TEM CD4+ lymphocytes expressing the TRP-1 TCR.           
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The most clinically significant evidence I present is the near total 
liquefaction of tumor following subcutaneous implantation in long-term secondary 
transplants. These results demonstrate not only potent antitumor activity 18 
months after initial transplantation, but the dense cellular trafficking of LV-TCR 
specific T cells.  While many adoptive immunotherapies have either maximized 
their therapeutic effect or been totally dependent upon the addition of cytokine 
administration, vaccination, myelodepletion (lethal irradiation or RAG KOs) or the 
use of immune modulators (α-CTLA-4) I elected to demonstrate this effect 
without such assistance (Overwijk et al, 2003; Quezada et al, 2010).  I propose 
that these freestanding antitumor effects were likely secondary to both the HP 
and the spontaneous TEM activation of TCR-specific cells.  In conclusion, I 
suggest that this novel translational model of immunotherapy, utilizing the unique 
properties of HSC transplantation, LV technology, and CD4+ T cells, has the 
opportunity to bring new medical care to patients with metastatic melanoma.  
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VI. Limitations and Future Directions 
Increased Efficiency of TCR Expression 
A major potential limitation is the inefficient expression of our bicistronic 
TCR gene in vivo.  I have shown in preliminary optimization studies that the F2A 
construct is superior to the IRES construct in expression of the TCR; however, 
the successful transcription and translation of such a long single protein chain 
might be limiting and reduce the expression of both gene products.  Moreover, a 
single general promoter such as CMV might not be sufficient to drive the 
expression of high levels of our bicistronic gene in developing lymphoid cells.  
Along with inefficient expression of both chains of the TRP-1 TCR, mismatched 
pairing of the α and β chain to endogenously expressed α and β chains may 
further reduce the functional efficiency of transduced lymphoid cells to recognize 
TRP-1.    
To address these concerns I have investigated the possibility of 
constructing a dual promoter lentiviral construct, with each chain of the TCR 
under the control of two separate promoters.  Although, the implementation of the 
natural lymphocyte specific CD2 promoter would be favorable, the CD2 promoter 
has never been shown to be a strong enough promoter to drive the expression of 
a TCR taken out of its natural context.   As such, I have focused my attention on 
two potent, general promoters, EF1α and CMV.  The use of independent dual 
internal promoters in a bicistronic lentiviral construct has shown increased 
expression of the transgenes in CD34+ HSCs as compared to a single promoter 
construct.  In particular, the dual promoter bicistronic constructs appear to be 
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advantageous in the expression of the downstream cistron (Yu et al, 2003; Ben-
Dor et al, 2006).  Furthermore, I am seeking to increase the efficiency of 
transduction by implementation of several other lentiviral envelope proteins such 
as the feline endogenous virus RD114 glycoprotein and the murine leukemia 
virus glycoprotein.  One or both of these alternative envelope proteins might 
prove to be either more effective or less toxic in transducing HSCs.   
Mechanisms of Autoimmune Vitiligo 
 These transplantation experiments with donor HSCs from both TRP-1 Tg 
mice and TRP-1 TCR lentivirus transduced HSCs have demonstrated consistent 
spontaneous autoimmune vitiligo.  Transplantation of GFP lentivirus transduced 
HSCs into irradiated mice did not develop vitiligo in prior experiments indicating 
that this phenomenon is an antigen specific event associated with the TRP-1 
TCR.  My data indicates that the myelodepletion of recipient mice coupled with 
the homeostatic proliferation of highly self-reactive TRP-1 TCR CD4+ T cells in 
the post transplant setting breaks the normal tolerance mechanisms leading to 
autoimmunity.  Furthermore, no other autoimmune responses were observed in 
TRP-1 TCR transduced HSC transplanted mice.  The autoimmunity appears to 
be a melanocyte specific response to the transplantation of TRP-1 TCR 
expressing HSCs.  The breaking of self-tolerance is a significant step in priming 
the immune system to promote tumor regression, and numerous studies have 
demonstrated autoimmune vitiligo as a side effect of melanoma immunotherapy 
in both mice and humans (Garbelli et al, 2005; Okamoto et al, 1998; Overwijk et 
al 1999).  The cellular mechanism of autoimmune vitiligo in melanoma immunity 
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is unknown.  Although, melanocyte destruction might ultimately depend on lysis 
by CD8+ effector T cells, Ihypothesize that the breaking of tolerance and 
development of vitiligo is a TRP-1 antigen specific CD4+ T cell dependent 
response.   The elucidation of the cellular mechanisms of autoimmune vitiligo is a 
future direction of the project.  I will establish a series of transplants with 
lentivirally transduced HSCs.  Both C57BL/6 and DR4 Tg mice will be 
transplanted with TRP-1 TCR lentivirus transduced HSCs.  Recipient mice 
developing autoimmune vitiligo will be analyzed at set intervals (onset of vitiligo, 
2, 4, 6, 8, 12 wks post onset of vitiligo).  Lymphocytes harvested from peripheral 
blood, spleen, bone marrow, and thymus will be characterized for phenotypic 
markers (CD45.1, CD45.2, CD3, CD4, CD8, CD25, Foxp3, human αβ TCR, and 
TRP-1 Ultimer) by antibody staining and flow cytometry.   As described 
previously, the epidermis of these mice will be fixed in formalin and sent for 
histologic staining for CD3, S-100, IL-2 and IL-17 to observe the lymphocytic 
infiltrations typically found in vitiligo. We will seek to characterize the cytokine 
profile of the lymphocytes by co-culture and subsequent ELISA and ELISPOT for 
IFN-γ, IL-2, and IL-17 as previously described.   
Lymphocytes harvested from the spleen of recipients developing vitiligo 
will be analyzed for activation status.  CD4+ T cells will be selected by using a 
Miltenyi Biotec CD4 Microbead Kit.  The CD4+ T cells will then be stained with 
antibodies for activation status markers CD44, CD45RB, CD62L, CD69, and 
CCR7 and phenotype markers CD4 and the TRP-1 Ultimer.  Analysis by flow 
cytometry should allow us to capture the activation status of the CD4+ T cells in 
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general and the TRP-1 TCR+ T cells in specific.  I have previously run this 
activation status experiment on naïve BoyJ and DR4 Tg mice splenocytes and 
will use the activation status marker profile from these prior experiments as the 
naïve control group for comparison to the vitiligo transplant mice.  In vitro 
experiments to test for melanocyte recognition and destruction will be established 
by directly placing splenocytes to an established HLA-DR expressing melanocyte 
culture with or without administration of various cytokines such as IL-2 and IL-17.     
After characterization of the lymphocytes and timing of the development of 
vitiligo in the transplanted mice we will establish two transplant groups (6 DR4 Tg 
mice per group) which will undergo either CD4+ or CD8+ T cell depletion by 
specific anti-CD4 and anti-CD8 antibodies from hybridoma cell lines (ATCC, 
Manassas, VA, USA).  Following irradiation and transplantation of either TRP-1 
TCR Tg HSCs or TRP-1 TCR lentivirus transduced HSCs, recipient mice will 
receive a total of six intraperitoneal injections of either rat anti-mouse CD4 (clone 
GK1.5) or rat anti-mouse CD8 (clone 2.43) monoclonal antibodies in a PBS 
solution.  Normal rat IgG will be used as a control group (Miyazaki et al, 2005).  
The exact timing of the injections will be set to occur prior to and during the peak 
occurrence of vitiligo as observed in the previous transplant group.  The 
transplanted mice will be carefully monitored for the development of vitiligo and 
lymphocytes collected from the peripheral blood will be analyzed by flow 
cytometry and antibody staining for CD45.1, CD45.2, CD3, CD4, CD8, and TRP-
1 Ultimer on weeks 4, 6, 8, 10, 12, 16, 20 and 24.  
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 Spontaneous autoimmune vitiligo is a significant development in our 
mouse melanoma model, and an understanding of the cellular mechanisms 
involved in the development of vitiligo in the transplanted mice could have 
potential implications for the ultimate goal of treating melanoma by 
transplantation of HSCs.  I fully expect that many of the lentivirus transduced 
HSC transplant recipients will develop vitiligo as in the previous experiments.  In 
the irradiated lymphodepleted mice, I suspect that the high expression of the 
TRP-1 TCR in the transplanted HSCs will overcome the normal tolerance 
mechanisms allowing for the selection and proliferation of these TRP-1 self-
peptide specific T cells.  The exact timing of the development of vitiligo and 
kinetics of lymphocyte development and activation will allow me to properly time 
the injections for CD4+ and CD8+ T cell depletion in vivo.  In the earlier 
transplants, low levels of lymphocytes became detectable around 4-6 weeks. The 
development of vitiligo will lag behind the reconstitution of the bone marrow 
following irradiation and transplantation.  My data indicates vitiligo to occur 
between 6-10 weeks post transplant    
Due to the limitations of formalin fixed paraffin embedded 
immunohistology, our analysis of lymphocytes in the skin has been limited to 
staining for CD3, S-100, and the cytokines IFN-γ, IL-2 and IL-17.  I am currently 
working to circumvent this limitation by developing a method to directly analyze 
the lymphocytes in the skin by flow cytometry.  The preliminary experimental 
approach involves the harvesting of lymphocytes from the skin of vitiliginous mice 
by disruption and enzymatic digestion by dispase and collagenase similar to 
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protocols used in the extraction of thymocytes from whole thymus used by other 
researchers.  In brief the procedure involves the harvesting of the entire 
epidermis from the mice, and subsequent disruption using a surgical scalpel.  
Following disruption, the tissue undergoes a series of digestions with 
collagenase and dispase.  The cellular mixture is then carefully layered over 
Ficoll plaque and centrifuged at 1200 rpm for 20 minutes.  The cellular layer is 
than subsequently collected for analysis.  Lymphocyte yields from this approach 
have been limited to approximately 50,000 cells per mice, which has been 
sufficient to perform simple flow cytometric analysis.  However, the results have 
been inconclusive.  I will continue to refine this technique to increase the yield 
and better characterize the phenotypes of the lymphocytic infiltrates 
demonstrated in the skin of the vitiligo mice.  
 The CD4+ and CD8+ T cell depletion experiments will allow for a better 
understanding of the roles that these two cells play in the development of 
autoimmune vitiligo.  Most likely, the CD8+ T cells act as the effector T cells that 
directly destroy the melanocytes and will be found to be necessary for the 
development of vitiligo.  However, I suspect that the TRP-1 specific CD4+ T cells 
are equally necessary for the development of vitiligo, either by release of IL-17 
and subsequent recruitment of inflammatory cells, or perhaps by activation of 
dendritic cells and subsequent increased presentation of antigen to naïve CD8+ T 
cells as in the cross presentation model discussed earlier.  Furthermore, it is 
possible that these TRP-1 specific CD4+ T cells might directly lyse melanocytes.         
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Skewing the T Cell Repertoire 
 Ther overall strategy of this thesis was to conduct a series of lentivirus 
transduced HSC bone marrow transplants as described above.  In future 
experiments I will seek to manipulate the reconstitution of the T cell repertoire by 
early vaccination of the transplanted mice with a recombinant vaccina virus 
encoding a gene for the human TRP-1 peptide (rVV-hTRP-1).  The optimal 
immunization schedule is unknown, therefore, I will implement immunization at 
two different time points (8 wks and 12 wks post transplant).  To measure the 
kinetics and effects of immunization I will analyze the transplanted mice at 
various time points (2, 4, 6, 8, 12, 16, 20, and 24 wks) and in various organs 
(thymus, spleen, inguinal lymph nodes, peripheral blood, and bone marrow).  As 
previously, I will concurrently transplant TRP-1 Tg Lin- cells into DR4 Tg recipient 
mice to use as a comparison group to the lentivirus transduced transplant group.    
I will analyze the lymphocytes from the various organs by flow cytometry 
implementing fluorescent antibodies to CD45.1, CD45.2, CD4, CD8, CD3, human 
αβ TCR, and TRP-1 Ultimer.  In addition I will seek to capture the activation 
status of the immune response by flow cytometry of various markers for naïve T 
cells (TRP-1 Ultimer, CD45.1+, CD4+, CD25low/int, CD44low, CD45RBhigh, 
CD62Lhigh, and CD69low), effector T cells (TRP-1 Ultimer, CD4+, CD25high, 
CD44high, CD45RBhigh , CD62Lint, CD69high), and memory T cells (TRP-1 DR4 
Ultimer, CD4+, CD25low, CD44high, CD45RBlow, CD62Llow, CD69low).    
I will seek to capture the functional capacity of the TRP-1 TCR CD4+ T 
cells to specifically recognize TRP-1 peptide in the context of HLA DR4 MHC 
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Class II molecule by ex vivo co-culture and ELISA and ELISPOT analysis for 
release of cytokines to peptide loaded APCs, tumor lysates, and whole tumors.  
Co-cultures will be established following the protocols previously described.  
ELISA and ELISPOT will be conducted by standard established protocols.  
I will further seek to manipulate the post transplant host environment to 
favor the repopulation of the T cell repertoire by administration of the homeostatic 
proliferation promoting cytokine, IL-7.  Increasing evidence indicates that post-
transplant administration of IL-7 increases T cell regeneration (Mackall et al, 
2001).   I will establish TRP-1 TCR lentivirus transduced HSC transplants as 
described above and test the effects of IL-7 on T cell survival and proliferation.  
IL-7 will be administered via intraperitoneal injection (10µg/injection) twice a day 
for seven consecutive days and started immediately after the first immunization, 
or not given at all (control arm). To control for non-specific mimicking of TCR 
signaling through IL-7, I will also incorporate a control immunogen using the 
MDA, gp100 (gene-gun gp100 plasmid or DC’s transduced with an adenovirus 
encoding gp100).  Fourteen days after the 3rd immunization with/without IL-7, 
animals will be sacrificed and tissues harvested (lymph nodes and spleen).  
Samples will then be assayed by flow cytometry for changes in frequency, 
absolute numbers, and activation status as previously described.  As before, 
changes in T cell function will be assessed using ELISPOT and ELISA assays for 
specific responses to TRP-1 peptide, tumor lysates, and whole tumor cells to 
measure changes in T cell avidity. 
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Tumor Immunity 
While this study has established the protective effects of LV-TCR 
transduced HSC transplantation to reject subcutaneous tumor, I have not tested 
the potential to treat established tumors.  I will test the capacity of the TRP-1 
TCR CD4+ T cells to mediate tumor immunity by a series of adoptive transfer 
experiments into recipient mice with previously established melanoma tumors.  
Subcutaneous tumors will be established in DR4 Tg mice by the injection of 
1x104 B16 tumor cells suspended in 100 µl of HBSS into the right and left flanks 
of 5 DR4 Tg mice 14 days prior to adoptive transfer.  Lymphocytes harvested 
from the spleen of TRP-1 TCR lentivirus transduced HSCs transplanted mice will 
be adoptively transferred at 1.5x107 splenocytes per mice via tail vein injection.  
Tumor volume will be assessed twice weekly using calipers to measure tumor 
growth or regression.  Tumor area will be calculated as the product of width and 
length.   
I will further seek to elucidate the cellular mechanisms of any observed 
tumor regression by selective adoptive transfer of either CD4+ or CD8+ T cells 
from the splenocytes of TRP-1 TCR transduced HSC transplant mice.  CD4+ and 
CD8+ T cells will be selected using a Miltenyi Biotec CD4+ and CD8+ Microbead 
Selection Kit and adoptively transferred into previously established melanoma 
injected in DR4 Tg recipient mice as described above.  Similarly, I will deplete 
individual T cell populations starting 3 days post transfer using antibodies specific 
for CD4+, CD8+, and CD25+ T cells.  Adoptive transfer experiments will be 
performed as described above with splenocytes from TRP-1 TCR lentivirus 
      78
transduced HSC transplant recipient mice.  Anti-CD4, anti-CD8, and anti-CD25 
antibodies from hybridoma cell lines will be administered as intraperitoneal 
injections (0.1 mg/mouse) every 3 days post adoptive transfer until the day of 
analysis.  Tumor width and length will be measured to assess tumor regression.     
 Active, specific, persistent tumor immunity is the ultimate goal.  As 
observed with the development of autoimmune vitiligo in the transplanted mice, 
the TRP-1 TCR is fully capable of recognizing TRP-1 peptide and actively 
mediating the destruction of TRP-1 expressing melanocytes in vivo.  The cellular 
mechanism and the role of CD4+ and CD8+ T cells in this antitumor response are 
unclear.  However, I hope to elucidate some of the basic roles played by these T 
cell populations with the T cell population depletion and specific CD4+ and CD8+ 
T cell adoptive transfer experiments.  Furthermore, I seek to better understand 
the post transplantation host conditions that will promote the survival and 
proliferation of our gene modified HSCs by immunization and administration of 
IL-7.  
Building on prior experiments investigating the basic effects of lentiviral 
transduction on HSC transplantation and elucidating the mechanisms of 
autoimmune vitiligo, I hope to address essential questions regarding enhancing 
tumor immunity by antigen presentation and transplantation of gene modified 
HSCs.  Ultimately, I hope that these findings can be the basis for a clinical trial 
with human patients with metastatic melanoma.   
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Table 1. Comparison of IRES and F2A lentiviral transduction experiments in 
Jurkat (JRT3) and human peripheral blood mononuclear cells (PBMC).   A 
lentiviral construct encoding the green flourescent protein (GFP) was used as 
a control group to test the efficiency of the transduction protocol.  Both the 
IRES and F2A constructs efficiently transduced JRT3 and PBMCs, however, 
the F2A construct proved to be more efficient, particularly in PBMCs at high 
multiplicities of infection (MOI) (p=0.012 at MOI of 30:1, p=0008 at MOI of 
100:1).       
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Table 2.  Analysis of CD4+ T cell compartment in LV-TCR transduced and 
TCR-Tg Lin- HSC transplants into either irradiated DR4 or C57BL/6 recipient 
mice (5 mice per group).  Peripheral blood mononuclear cells were collected 
and stained with fluorescent antibodies for murine CD3, CD4, CD8, CD45.1 
and the TRP-1 pentamer at 6 months post transplantation.  Antibody binding 
to surface markers was measured by flow cytometry as previously described.    
At 6 months transplantation there was no statistical difference between the LV-
TCR transduced and TRP-1 Tg transplant groups (33%+/-4.6 vs 38%+/-7.5).  
The LV-TCR transplants into C57BL/6 recipients also exhibited Ultimer speci-
ficity at 25%+/-4.7.  LV-GFP was used as a transduction and transplant control 
group.  In the LV-TCR/DR4 transplant group, 64%+/-4.1 of CD45.1+/CD3+/
CD4+ T cells were specific for the TRP-1 Ultimer.   
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Table 3.  IFN- release as measured by ELISA in spleno-
cytes harvested  from LV-TCR transplants 12 months post 
transplantation. Cell media (CM), negative control peptide 
(HA), TRP-1277-297 epitope at increasing concentrations 
(TRP1), control 1102 melanoma cells (1102 mel), and 624 
melanoma whole tumor cells pretreated with IFN (624 Mel + 
IFN).   
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Table 4.  Summary of development of spontaneous autoimmune vitiligo in all 
transplant groups. The development of vitiligo as measured by external phe-
notypic changes in coat color was recorded for all transplant groups.  As 
shown in the table the development of vitiligo was dependent on the presence 
of the TRP-1 TCR (via lentiviral transduction or the TCR transgenic) and the 
proper MHC class II DR4 element (via the competitor BM).    
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Figure 1.  Central role of CD4+ T cells in tumor immunity.  CD4+ T cells are in-
volved in: 1. The induction and maintenance of CD8+ T cells.  2. The activation 
of antigen presenting cells (APC) 3. the upregulation of MHC molecules. 4. 
Enhanced antigen processing.  5. B-cell isotype switching. 6. Direct cytolysis 
of tumor cells.  
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Figure 2.  Cloned  and  TCR subunits of TRP-1/DR4 Clone-2.  The specific 
VDJ regions of the  and  chains were analyzed and identified using the V-
QUEST search engine from the IMGT website (http://imgt.cines.fr/
IMGT_vquest/vquest?livret=0&Option=humanTcR).   
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Figure 3.  Schematic diagrams of the TRP-1 TCR lentiviral constructs.  A.  
Schematic of lentiviral constructs implementing either an internal ribosomal 
entry site (IRES) or Furin self-cleavage site (2A) between genes encoding the 
a and b chains of the TRP-1 epitope specific TCR.  B.  Detailed diagrams of 
the TRP-1 TCR lentiviral constructs.  The non-specific general promoter of the 
cytomeglovirus (CMV) was chosen to drive the expression of the downstream 
a and b chains.    
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Figure 4. Comparison of IRES and F2A lentiviral transduction experiments in 
human peripheral blood mononuclear cells (PBMC).   Both the IRES and F2A 
constructs efficiently transduced PBMCs, however, the F2A construct proved 
to be more efficient, particularly in PBMCs at high multiplicities of infection 
(MOI) (p=0.012 at MOI of 30:1, p=0008 at MOI of 100:1).       
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Figure 5.  Representative flow cytometry results for lentiviral transduc-
tion of human CD34+ and murine Lin- cells with the TRP-1 TCR F2A len-
tiviral construct.  A gp100 specific pentamer was used as a negative 
control to gauge the background non-specific binding of pentamer com-
plexes, shown in row 1.  A lentivirus encoding the green fluorescent pro-
tein (GFP) was used as a positive control for the transduction protocol 
as shown row 3.   Flow cytometric analysis was performed 72 hours 
post transduction using a TRP-1 TCR specific Ultimer (Proimmune, 
Inc.).   
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Figure 6.  Lentiviral constructs efficiently transduce murine Lin- cells and 
leads to high expression of transduced gene (28.7%+3)  A lentivirus encoding 
the green fluorescent protein (GFP) was used as a positive control for the 
transduction protocol (56.2%+8) Flow cytometric analysis was performed 72 
hours post transduction using a TRP-1 TCR specific Ultimer (Proimmune, 
Inc.).  A gp100 specific Ultimer was used as a negative control to gauge the 
background non-specific binding of pentamer complexes. The results repre-
sent five separate transduction experiments with at least 3 wells of independ-
ent cells in each group.    
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Figure 7. Peripheral blood mononuclear cells transduced with LV-TRP1-F2A 
(LV-TCR) are functionally specific. Specific IFN- production detected by ELI-
SA to the specific peptide (TRP-1277-297), lysate (B16) and intact tumors (B16-
DR4, 624 Mel pretreated with IFN-, and 1102 Mel stably transduced with TRP
-1), but not to the control peptide (HA306-318), control lysate (MC38) or control 
tumors (wild type B16, MC38-DR4, and 1102 Mel stably transduced with 
GFP). Interactions with TRP-1277-297 pulsed targets were blocked by L243 
(HLA-DR) and L3T4 (CD4), but not by control W6/32 (class I) or HIT8a (CD8) 
antibodies. All peptides were pulsed onto DR4+ 1088 EBV-B cells at 50 M x 3 
hrs.  
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Figure 8.  Positive selection of the TRP-1 TCR following crossbreeding into 
DR4 Tg mice.  Peripheral blood cells were stained for CD3, CD4 and the TRP-
1 Pentamer in both TRP-1 TCR Tg mice and TRP-1 TCR/DR4 Tg mice.  Each 
group contains at least 5 mice that were individually bled, stained and ana-
lyzed by flow cytometry.  In the TRP-1 TCR Tg mice, levels of pentamer posi-
tivity was near that of negative controls and ranged from 2-7% in CD4 T cells 
(Lighter shaded bars).  Once crossed on to the HLA-DR4 Tg mice, nearly 80% 
of CD4 T cells in the peripheral blood were specific for the TRP-1 Ultimer 
(Darker shaded bars). Within the CD4 cells, 79% ± 8.3% versus 6.4% ± 1.0%; 
P < 0.0001. Data (mean ± SEM with P value; n = 5–7 per group) 
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Figure 9.  Gene modified HSCs successfully engraft and repopulate transplant 
host over 6 months.  CD45.1/CD45.2 competitive repopulation involving co-
transplantation of GFP transduced Lin- BoyJ (CD45.1) HSCs and unmanipulat-
ed congenic bone marrow cells from a C57BL/6 mouse (CD45.2) transplanted 
into irradiated DR4 Tg recipient mice.  A. Transplanted, transduced Lin- cells 
maintain GFP expression in the peripheral blood (CD45.1+/GFP+) , developing 
into a high percentage of mature T cells (TCR+/CD3+) and CD4+ T cells.  B. 
Gene modified cells area also present and remain stable in within the spleen.  
C. Developing double positive (CD4+/CD8+/GFP+) thymocytes carrying GFP 
are also identified and maintained in the thymus.  D. Gene modified donor 
cells (CD45.1+/GFP+) are also stable in the bone marrow. Percentages repre-
sent 5 mice in each group, for each time point.  
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Figure 10. Representative flow sample shows successful engraftment and 
emergence of lymphocytes 1 and 4 months post transplantation with either LV-
TCR transduced Lin- HSCs (LV-TCR/DR4) or TCR-Tg Lin- HSCs (TCR-Tg/
DR4) into irradiated DR4 recipient mice. At 1 month post transplant, few CD4 
staining cells are seen in the peripheral blood (1.1% in the LV-TCR/DR4 and 
3.6% in the TCR-Tg/DR4).  By 4 months post transplantation lymphocytes 
(both CD4+ and CD8+) have reconstituted the peripheral blood.  Of the mature 
CD3+/CD4+ T cells 43.3% and 43.8% stain positive for the TRP-1 Ultimer in 
the LV-TCR/DR4 and TCR-Tg/DR4 groups, respectively.  Data are representa-
tive of flow cytometry studies done on 4 separate transplant experiments.  
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Figure 11.  Transplantation of LV-TCR and TRP-1 TCR Tg Lin- HSCs results 
in high expression of TRP-1 specific TCR.  As previously described, competi-
tive bone marrow transplants were established with LV-TCR transduced and 
TRP-1 Tg lineage depleted BM cells and transplanted into irradiated recipient 
DR4 Tg and C57BL/6 mice.  Peripheral blood was obtained at 1 and 4 months 
and stained with PE labeled TRP-1 pentamer, APC labeled anti-CD4 antibody, 
and PE-CY5 labeled anti-CD3 antibody.  At 1 month post transplantation (grey 
bars), TRP-1 pentamer specific lymphocytes constituted less than 5% of the 
total circulating CD3+/CD4+ lymphocytes in all transplant groups.  At 4 months 
post transplantation (blue bars), the LV-TCR in DR4 Tg recipients (LV-TCR/
DR4) had the highest percentage of circulating TCR specific CD3+/CD4+ T 
cells at 15.8%+/-2, followed closely by the TCR-Tg in DR4 Tg recipients (TCR-
Tg/DR4) at 11.6%+/-2.5.  The LV-TCR in C57BL/6 group only expressed the 
specific TCR in 8.2%+/-2 of CD3+/CD4+ cells, statistically less than the LV-
TCR/DR4 group (p<0.05).  A control group of LV-GFP transduced HSCs in 
DR4 Tg recipients (LV-GFP/DR4) only expressed GFP in 5.5%+/-1 of CD3+/
CD4+ T cells at 4 months.  
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Figure 12.  12 month analysis of LV-TCR and TRP-1 TCR Tg Lin- HSCs trans-
planted into DR4 Tg mice (n=10 for each group).  Percent TRP-1 Ultimer posi-
tive as a function of total number of peripheral mononuclear cells.  Results 
show high expression of TRP-1 specific TCR in both groups with TRP-1 TCR 
Tg transplants expressing higher numbers after 4 months. At 12 months, 8% ± 
1.7% versus 22.6% ± 1.5%; P = 0.001. As previously described, competitive 
bone marrow transplants were established with LV-TCR transduced and TRP-
1 Tg lineage depleted BM cells and transplanted into irradiated recipient DR4 
Tg mice.  Peripheral blood was obtained at 1,2,4,6, and 12 months and 
stained with PE labeled TRP-1 Ultimer, FITC labeled anti-CD8 antibody, APC 
labeled anti-CD4 antibody, and PE-CY5 labeled anti-CD3 antibody.   
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Figure 13.  12 month analysis of LV-TCR and TRP-1 TCR Tg Lin- HSCs trans-
planted into DR4 Tg mice (n=10 for each group).  Percent TRP-1 Ultimer posi-
tive as a function of CD3+ peripheral mononuclear cells.  Results show high 
expression of TRP-1 specific TCR in both groups, but TRP-1 TCR Tg trans-
plants expressed higher percentages at all time points. At 12 months, 17.8% ± 
2.3% versus 36.7% ± 2.4%; P = 0.006.  As previously described, competitive 
bone marrow transplants were established with LV-TCR transduced and TRP-
1 Tg lineage depleted BM cells and transplanted into irradiated recipient DR4 
Tg mice.  Peripheral blood was obtained at 1,2,4,6, and 12 months and 
stained with PE labeled TRP-1 Ultimer, FITC labeled anti-CD8 antibody, APC 
labeled anti-CD4 antibody, and PE-CY5 labeled anti-CD3 antibody.   
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Figure 14.  12 month analysis of LV-TCR and TRP-1 TCR Tg Lin- HSCs trans-
planted into DR4 Tg mice (n=10 for each group).  Percent TRP-1 Ultimer posi-
tive as a function of CD4+ peripheral mononuclear cells.  Results show high 
expression of TRP-1 specific TCR in both groups, but TRP-1 TCR Tg trans-
plants expressed higher percentages at all time points. At 12 months, 26.1% ± 
2.4% versus 65.2% ± 6.3%; P = 0.004.  As previously described, competitive 
bone marrow transplants were established with LV-TCR transduced and TRP-
1 Tg lineage depleted BM cells and transplanted into irradiated recipient DR4 
Tg mice.  Peripheral blood was obtained at 1,2,4,6, and 12 months and stained 
with PE labeled TRP-1 Ultimer, FITC labeled anti-CD8 antibody, APC labeled 
anti-CD4 antibody, and PE-CY5 labeled anti-CD3 antibody.   
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Figure 15.  Analysis of thymocytes in LV-TCR HSC transplanted DR4 Tg 
mice.  At 12 months the thymus from LV-TCR transplants were harvested and 
analyzed by flow cytometry.  A. This representative flow sample exhibits our 
analysis technique.  Thymocytes were stained for TRP-1 Ultimer, CD3, CD4, 
and CD8.  Each compartment of the maturing thymocyte population (double 
negative, double positive, and CD4 and CD8 single positive) were analyzed for 
TRP-1 Ultimer positivity.  B. Summary of TCR gene expression in DN, DP, SP 
CD8, SP CD4 subpopulations. 36% of DN thymocytes, 45% of DP thymo-
cytes, 15% of CD8+ thymocytes, and 13% of CD4+ thymocytes expressed the 
TRP-1 TCR. As expected, a large percentage of cells are deleted from the 
double positive stage to the mature single positive stage of central thymic se-
lection. DP 45% ± 7.3% versus SP CD4 13.3% ± 3.1%; P = 0.002. Data (mean 
± SEM with P value; n = 4–6 per group).  
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Figure 16.  Development of spontaneous autoimmune vitiligo in mice trans-
planted with LV-TCR Lin- bone marrow cells.  Depigmentation of the hair folli-
cles in the vitiliginous mouse (right) exhibits an irregular, spotted pattern.  A 
control transplant mouse (left) is shown for comparison.      
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Figure 17.  Skin samples of LV TRP-1 TCR BM transplanted mice that devel-
oped spontaneous autoimmune vitiligo.  The samples were fixed in paraffin 
and stained for S-100 (a marker for neurocrest derived cells such as melano-
cytes) and mouse CD3.  The top two panels show the staining pattern in the 
skin of a normal immune replete control mouse.  Melanocytes typically reside 
around the hair follicles as highlighted by the dotted circles  (Slide1), and few 
lymphocytes are found in normal skin (Slide 2).  In the vitiliginous mice, there 
is a clear loss of melanocytes  around the hair follicles in affected skin areas 
as indicated by the arrow in Slide 3.  Unlike normal skin in vitiliginous skin, a 
profuse lymphocytic infiltration particularly around the hair follicles is observed 
(Slide 4).     
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Figure 18.  Skin samples of  LV TRP-1 TCR BM transplanted mice that devel-
oped spontaneous autoimmune vitiligo.  The left two panels show paraffin em-
bedded staining for S-100 and CD3 as previously described.  The right two 
panels show frozen section samples of vitiliginous skin stained with antibodies 
specific for murine CD4 and CD8, respectively.   
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Figure 19. Vitiligo is associated with gross distortion of the natural skin archi-
tecture, melanocyte destruction, and TCR gene specific CD4+ T cell infiltration. 
Immunohistochemistry staining at 6 month post-transplantation of paraffin-
embedded skin sample from LV-TCR transplant with antibody specific for hu-
man-TCR-. 
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Figure 20. Representative flow cytometry analysis of splenocytes from 
transplant experiments. Transplant recipients exhibit a TEM phenotype and 
react spontaneously to tumor ex vivo. Peripheral blood samples at 6 
months post-transplantation were obtained and stained with antibodies 
against CD4, TRP1-Ulimter, CD44, CD45RB, and CD62L. LV-TCR trans-
plant CD4+/Ultimer+ cells exhibit a memory-effector (TEM) phenotype 
(CD45RBlow, CD62Llow, CD44high), while the polyclonal CD4+/Ultimer- and 
CD4+ control population exhibit a more generalized effector profile 
(CD45RBhigh, CD62Lint, CD44high), contrasting with naïve CD4+/Ultimer+ 
cells (CD45RBhigh, CD62Lhigh, CD44low) from endogenous non-transplanted 
TCR Tg. 
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Figure 21.  Summary of activation status of all CD4+ subpopulations. Trans-
plant recipients exhibit a TEM phenotype and react spontaneously to tumor ex 
vivo. Peripheral blood samples at 6 months post-transplantation were obtained 
and stained with antibodies against CD4, TRP1-Ulimter, CD44, CD45RB, and 
CD62L. LV-TCR transplant CD4+/Ultimer+ cells exhibit a memory-effector 
(TEM) phenotype (CD45RBlow, CD62Llow, CD44high), while the polyclonal CD4+/
Ultimer- and CD4+ control population exhibit a more generalized effector pro-
file (CD45RBhigh, CD62Lint, CD44high), contrasting with naïve CD4+/Ultimer+ 
cells (CD45RBhigh, CD62Lhigh, CD44low) from endogenous non-transplanted 
TCR Tg. Data (mean ± SEM; n = 5 per group). 
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Figure 22. CD4+ T cells from secondary transplant recipients exhibit high level 
gene specific TCR expression. Peripheral blood from 6 month secondary 
transplants were stained with antibodies against CD4, CD8, CD3 and the TRP
-1 pentamer and analyzed by flow cytometry. Total, CD3, and CD4 popula-
tions: 7.1% ± 4.5% within the total cellular compartment (CD45+Ultimer+), 
47.5% ± 8.3% within the global CD3 compartment (CD45+CD3+Ultimer+), and 
53.1% ± 10.7% within the CD4 subcompartment (CD45+CD3+CD4+Ultimer+). 
Data (mean ± SEM;n = 5 per group) 
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Figure 23. CD4+ T cells from secondary transplant recipients exhibit high level 
gene specific TCR expression and multi-copy integration of the LV-TCR gene 
product.  A. Relative TCR gene expression is >1000 times greater than control 
transplants (P=0.01). Total RNA was prepared from BM obtained from 6 month 
old secondary LV-TCR and Control transplants and analyzed by qPCR for rel-
ative TCR gene expression using an -chain specific probe. Relative gene ex-
pression (RQ = LV-TCR/Control) is displayed. B. Multicopy integration of the 
LV-TCR gene product is found in secondary transplant recipients. Using a vec-
tor backbone specific probe, 4-6 integrants were identified in three separate 
LV-TCR transplant samples compared with Control. 
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Figure 24. Six month secondary TCR transplant recipients reject subcutane-
ous melanoma. LV-TCR and control transplants (5 mice per group) were sub-
cutaneously injected with 5x105 B16-DR4 tumor cells. Three days after injec-
tion, tumor size was recorded. Data are displayed as mean ± SEM with P val-
ue; n = 5 per group. Statistical significance between groups was based on tu-
mor size using a Student T-test. Experiments were performed in a blinded, 
randomized fashion, and executed independently 3 times.  
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Figure 25. Tumors from LV-TCR secondary transplants are necrotic.  Im-
munohistochemistry staining of paraffin-embedded tumors resected from 6 
month transplants.  A.  Resected tumor cells were stained with antibody spe-
cific for murine CD3.  Panel 1 shows B16-DR4 tumors from control transplant.  
Panel 2 shows tumor from LV-TCR transplant.  B.  H&E staining of tumor re-
sections from control transplant (Panel 1) and LV-TCR (Panel 2) shows ne-
crotic changes in LV-TCR transplant.   
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Figure 26.  Paraffin-embedded tumor resection from LV-TCR secondary trans-
plant with immonhistochemistry staining specific for human TCR- chain ex-
pression.  Tumors from LV-TCR secondary transplants exhibit lymphocytic in-
filitration expressing human TCR- 
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Figure 27.  LV-TCR gene-modified human CD34+/CD38- HPCs obtained from 
cord blood functionally engraft and repopulate 6 month old NOD-SCID-IL2r 
KO transplant recipients. A, Flow cytometry analysis of peripheral blood 
demonstrates high level TCR gene expression: hCD45/mCD45.2/CD4/CD8/
Ultimer staining. B, Six month transplant summary of TCR gene expression 
within the hCD45+/CD4+/Ultimer+ subpopulation.  Data are displayed as mean 
+ SEM; n = 5 per group.  
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Figure 28.  LV-TCR transplants in NOD-SCID-IL2r KO recipients reject hu-
man melanoma implantation.  6 month old control and LV-TCR transplants (5 
mice in each group) were injected subcutaneously with 5x105 human 624 
melanoma cells at Day 0.  Tumor size was measured every 3 days for 24 
days.  No tumor was visibly observable in any of the LV-TCR transplants 
through 24 days post-tumor implantation, while all 5 mice in the control trans-
plants developed visibly observable tumors between 9 and 12 days.   
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